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ABSTRACT 
AHYEON KOH: Nitric Oxide-Releasing Polyurethane Membranes For Implantable 
Electrochemical Glucose Sensors 
(Under the direction of Professor Mark H. Schoenfisch) 
 
The development of novel biocompatible membranes is key to mitigating the host 
foreign body response (FBR) that limits the utility of implantable electrochemical 
biosensors for continuous glucose monitoring. Nitric oxide (NO)—an endogenously 
produced physiological mediator involved in wound healing, angiogenesis, and the 
inflammatory response—has been shown to reduce the FBR and may enhance sensor 
utility when released from sensor membranes.  
 Nitric oxide-releasing glucose sensor membranes with tunable release kinetics 
and total payloads were fabricated utilizing polyurethane (PU) films doped with NO 
donor-modified silica nanoparticles. A wide range of NO-release fluxes (5−460 pmol cm-
2 s-1) and durations (16 h to 14 d) were achieved by altering the type of dopant, as well as 
the PU sensor membrane composition and concentration. Sensor performance was 
affected by water uptake and membrane thickness regardless of the type of NO-release 
vehicle. 
 To combine the potential benefits of both NO-release and porous scaffolds in one 
engineered material, NO-releasing fibrous PU membranes were fabricated via 
! iv!
electrospinning. Electrospun PU fibers doped with NO-releasing silica particles exhibited 
a wide range of NO-release totals and durations (7.5−120 nmol mg-1 and 7 h to 14 d, 
respectively). These materials exhibited ~83% porosity with flexible plastic or 
elastomeric behavior, and a wide range of fiber diameters (119−614 nm) and mechanical 
strength (moduli of 1.7−34.5 MPa).  
Nitric oxide-releasing electrospun fibers were applied to needle-type glucose 
sensors as the outermost membrane. The NO-releasing dendrimer-doped PU fiber mats 
maintained their porosity in serum without dendrimer leaching. Sensor performance was 
not significantly impacted by the additional porous membrane (≤50 µm thickness). The 
glucose sensitivity was 2.4 ± 1.6 nA/mM with a dynamic range 1–24 mM, indicating 
clinically acceptable performance.  
 In vivo analytical sensor performance was assessed using NO-releasing 
membrane-modified glucose biosensors in a porcine model. The NO-releasing sensors 
were shown to continuously monitor glucose for one week with 91.8% of determinations 
indicated as clinically accurate and acceptable. This research illustrated the ability to 
create functional NO-releasing glucose sensors so future studies can focus on thoroughly 
evaluating the benefits of NO release and porosity on in vivo analytical performance. 
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CHAPTER 1: BIOCOMPATIBLE MEMBRANES FOR IMPLANTABLE 
ELECTROCHEMICAL GLUCOSE SENSORS  
 
Text, tables, and figures are adapted and reprinted with permission from the corresponding journal. 
Original articles are two papers: (1) a review article co-authored with Scott P. Nichols and Mark H. 
Schoenfisch published in Journal of Diabetes and Science Technology in 2011, titled “Glucose sensor 
membranes for mitigating the foreign body response”, vol. 5 (5), pp 1052-1059; and (2) a review article co-
authored with Scott P. Nichols, Wesley L. Storm, Jae Ho Shin, and Mark H. Schoenfisch published in 
Chemical Reviews in 2013, titled “Biocompatible materials for continuous glucose monitoring devices”, 
vol. 113 (4), pp 2528-2549.  
1.1 Electrochemical continuous glucose monitoring biosensors 
1.1.1 Overview of implantable electrochemical glucose sensors 
Diabetes mellitus is a worldwide epidemic characterized by chronic 
hyperglycemia that results from either a deficiency in or tolerance to insulin.1 In the 
United States, 8.3% of the population currently suffers from diabetes, with that number 
projected to increase to 1 in 3 adults by 2050 if current trends continue.2 Consequently, 
diabetes is the seventh leading cause of death in the United States with an annual cost 
burden of $174 billion.2  
Blood glucose levels in diabetics fluctuate significantly throughout the day, which 
can result in serious complications, including heart attacks, strokes, high blood pressure, 
kidney failure, blindness, and limb amputation.1,2 Therefore, diabetes patients should use 
potable glucose sensors to monitor blood glucose levels and manage insulin levels to 
reduce the morbidity and mortality of diabetes mellitus. As such, glucose sensors 
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represent more than 85% of global market for biosensors in medical diagnostics.3,4 The 
traditional glucose monitoring techniques are primarily based on the use of 
electrochemical amperometric glucose sensors. The most successful technologies for 
measuring glucose concentrations are based on enzyme-modified electrodes and 
electrochemical amperometric detection with a number of useful designs. In 1967, 
Updike and Hicks first developed a sensor that detects glucose by monitoring the 
consumption of oxygen using two oxygen electrodes (one covered with the enzyme and 
one for reference), comparing the differential current between these electrodes to correct 
for background variations in oxygen.5 Alternatively, hydrogen peroxide produced 
enzymatically by glucose oxidase can be quantified amperometrically to indirectly 
determine glucose concentration, as first demonstrated by Guilbault and Lubrano in 
1973.6 Amperometric enzyme-based glucose sensors vary greatly in electrode design, 
electrode material, enzyme immobilization method, and polymeric membrane 
compositions. To date, the U.S. Food and Drug Administration (FDA) has approved more 
than 25 glucose monitors, with the majority employing test strips consisting of either 
glucose dehydrogenase (GDH) or glucose oxidase (GOx) immobilized on a screen 
printed electrode.4 The analysis is based on obtaining a small blood sample (<1 µL) 
through a finger prick that is subsequently introduced into the test strip via capillary 
action.4,7 
While such measurements have augmented the health outcomes for people with 
diabetes by improving blood glucose management, in vitro glucose monitoring only 
provides instantaneous blood glucose concentrations that are unable to warn of emerging 
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hyper- or hypoglycemic conditions. Additionally, the sample collection (i.e., finger prick) 
method is inconvenient and can be painful for adolescents, resulting in poor patient 
compliance. Analytical methods that enable continuous monitoring of blood glucose have 
thus been sought.8 Continuous glucose monitoring (CGM) provides real-time information 
on trends (i.e., whether the glucose levels are increasing or decreasing), magnitude, 
duration, and frequency of blood glucose fluctuations during the day.8,9 Ideally, 
analytically functional CGM devices could be linked to an insulin delivery pump, 
creating an artificial pancreas.8,9 
 The development of continuous glucose monitoring technologies is predominantly 
focused on subcutaneously implanted amperometric electrochemical glucose sensors.10 
Due to the high selectivity and sensitivity afforded by the specific biocatalytic reactions 
of an immobilized enzyme and the prospect of miniaturization, electrochemical 
biosensors are among the most widely studied and commercially available devices.4 
Implantable electrochemical sensors measure the rate of glucose oxidation as a change in 
oxygen or hydrogen peroxide concentration upon reaction of glucose with a glucose-
specific enzyme (e.g., GOx or GDH), similar to in vitro glucose sensors. First generation 
enzyme-based electrochemical biosensors were fabricated by immobilizing the enzyme 
on the surface of the electrode. The enzyme is reduced upon converting glucose to 
gluconolactone with ambient oxygen facilitating the conversion of the reduced enzyme 
back to its oxidized form with concomitant production of hydrogen peroxide.4,11  
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Figure 1.1. The enzymatic oxidation of glucose to gluconolactone by glucose oxidase 
with subsequent electrochemical detection of oxygen depletion and/or hydrogen peroxide 
formation. 
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 The glucose concentration correlates with the amperometric signal obtained from 
either the electrochemical oxidation of produced hydrogen peroxide or the reduction of 
consumed oxygen (Figure 1.1). Although enzyme-based electrochemical glucose 
biosensors are characterized with high selectivity and sensitivity due their enzymatic 
nature, the dynamic range of such sensors is limited by the co-substrate (i.e., oxygen) 
availability. An outer diffusion limiting membrane is often employed and eliminates 
oxygen deficiency problems, albeit with slightly delayed sensor response. Additionally, 
the working electrode potential required to monitor hydrogen peroxide (i.e., ~ +0.6 V vs. 
Ag/AgCl) will also oxidize electroactive endogenous species (e.g., ascorbic acid and 
acetaminophen) and create high current densities.11 To address these shortcomings, other 
electrochemical glucose biosensors designs have employed electron mediators (e.g., 
[Os(4,4’-dimethoxy-2,2’-bipyridine)2Cl]+/2+) “wired” to the enzyme on a hydrophilic 
polymer matrix (e.g., poly(vinylpyridine) or poly(vinylimidazole)). Such mediators are 
capable of shuttling electrons from the redox center of the enzyme to the surface of the 
electrode, allowing for a lower applied electrode potential.12,13 In turn, the sensor 
response becomes independent of the co-substrate and interferences. Unfortunately, most 
mediators are toxic and competition between the mediator and oxygen still exists.9,11 The 
concept however has evolved to where the enzyme cofactor is covalently linked to the 
electrode, enabling direct electron transfer through the wiring nano-material (e.g., carbon 
nanotube). Toxicity still remains a concern for in vivo use.   
 6 
  
Figure 1.2. Sensor design percutaneous (left) and fully implantable subcutaneous 
(right) electrochemical glucose biosensors.  
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 Enzyme-immobilized amperometric biosensors have been implanted fully 
subcutaneously for month to years or percutaneously for <1 month, and most often only 
3–5 days. Subcutaneous glucose sensors generally consist of a disk-type sensor with a 
titanium housing and measure oxygen consumption (Figure 1.2 right). Gough et al. 
reported on a subcutaneous sensor design based on differential electrochemical detection 
of oxygen via a two-step chemical reaction catalyzed by glucose oxidase and catalase.14 
Accurate glucose measurements were carried out for >1 year by taking into account the 
difference in oxygen reduction at a working electrode producing a glucose-modulated 
current and a reference electrode producing an oxygen-dependent current.14 Sensor 
(oxygen) response changes due to collagen encapsulation, variations in local 
microvascular perfusion, and limitations in oxygen availability were thus relative, 
reducing the demand of device calibrations. The subcutaneous nature of the sensors likely 
minimizes any micromotion effects that also elevate the foreign body response (FBR).15 
Unfortunately, implantation and subsequent replacement of the sensors required surgery, 
with each instance followed by a long (~2–3 week) stabilization period. Faulty devices 
for whatever reason would be costly to remove and/or replace. The size of the sensor is 
also significantly larger than percutaneous CGM systems (~3 cm vs. 350 µm) due to 
power (i.e., battery) requirements to support long-term use.  
 Percutaneous needle-type microsensors monitor hydrogen peroxide production 
amperometrically as a measure of the glucose concentration (Figure 1.2, left).9,16,17 The 
sensing cavity generally consists of a Pt-Ir wire working electrode coated with three 
functional layers: an inner-selective layer, an enzyme layer, and the outer diffusion 
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limiting membrane. Though such sensors are characterized as having a shorter 
stabilization period (e.g., 2‒4 h) compared to subcutaneous glucose sensors, the device 
penetrates through an opening in the dermis with concomitant infection and dislodging 
risks. Additionally, frequent calibration (e.g., >2 times per day) using intermittent 
glucose monitoring (via finger pricks) is required due to erratic analytical performance. 
The percutaneous nature of the device creates additional forces on the sensor that can 
lead to even greater inflammation.15 In this regard, compliance regarding the use of such 
devices remains poor. Nevertheless, only percutaneous implantable electrochemical 
glucose sensors are currently FDA approved and commercially available among the 
various continuous glucose monitoring technologies.18  
1.1.2 Implantable glucose sensor design and challenges for bioanalytical performance 
 Reliable in vivo glucose sensing can be achieved based on understanding 
physiology and biological response. A number of interferents (e.g., acetaminophen, 
ascorbic acid, and uric acid) can affect sensor response, as they are also electroactive at 
the electrode potential used to oxidize hydrogen peroxide. Permselective sensor 
membranes via size exclusion and/or electrostatic repulsion are often used to improve the 
selectivity of implantable glucose sensors.4 The range of polymeric materials that have 
been evaluated as effective permselective films include cellulose acetate, Nafion, 
electropolymerized films (e.g., polyphenol), and multilayer hybrids of these polymers.4,19 
Polyphenol permselective membranes are able to electropolymerize within an enzyme 
layer and the film thickness is self-limiting (10–100 nm) in a controllable manner, 
making this approach attractive for reducing interferences.20,21 In some cases, such 
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membranes also exclude surface-active macromolecules (i.e., proteins and platelets), 
protecting the electrode from biofouling.4  
 Since the electrochemical detection of hydrogen peroxide requires oxygen, a 
cofactor in the GOx enzymatic reaction, oxygen concentration and fluctuation in vivo 
should be accounted for sensor design. Oxygen concentration in interstitial fluid is 
approximately ten times lower than the concentration of glucose resulting in an “oxygen 
deficit” state. Low concentrations of oxygen lead to problems with the biosensor 
response to glucose (particularly sensor sensitivity and linearity) due to stoichiometric 
imbalance between the two cofactors.11,22 Moreover, subcutaneous oxygen tension for 
humans ranges from 40 (~5 kPa) to 130 mm Hg (~17kPa) with partial pressures affected 
by anesthetics and hypoxia at the implantation site.23 Sensor performance issues due to 
changing oxygen levels are exacerbated by the foreign body response (FBR) that results 
in local consumption of oxygen and glucose by inflammatory cells at the vicinity of the 
sensor. Additionally, oxygen diffusion to the sensor decays exponentially after sensor 
implantation due to changes in tissue permeability.14 To overcome oxygen deficiency, 
polymeric membranes such as polyurethane, Nafion, silicone elastomer, polycarbonate, 
and layer-by-layer assembled polyelectrolytes are utilized to reduce glucose diffusion.24-
28 Polyurethane in particular is widely used as an outermost membrane of implantable 
glucose sensor to overcome this complication by controlling the oxygen/glucose ratio 
with sufficient dynamic range.29 Implantable glucose sensors exhibiting dynamic ranges 
up to >12 mM have been shown to exhibit no oxygen dependency in vivo.29 
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 In addition to the issue of electroacitve interference and oxygen deficit for sensor 
fabrication, patient variability and physiological fluctuation are equally important factors 
for CGM device utility. Since percutaneous sensors are implanted through the epidermis, 
dermis, and subcutaneous layers, the effects of tissue heterogeneity are relevant to the 
analytical performance of the sensor. Temporal and spatial glucose dynamics are both 
influenced by tissue composition, distribution, and thickness.30-32 Temperature 
fluctuations in subcutaneous tissue will also impact sensor performance by altering 
glucose oxidase activity.33 Additionally, external pressure (e.g., posture change) on the 
CGM sensor has also caused erratic analytical performance.34 Such behavior is attributed 
in part to blood occlusion due to pressures applied to the tissue adjacent to the sensor.15,35 
Moreover, these performance limitations may be more pronounced in diabetic patients 
due to differences in physiology.36 Therefore, these fluctuations and their possible impact 
on interstitial fluid physiology demand careful attention when characterizing in vivo 
sensor performance. 
1.2 Biocompatibility concerns for subcutaneously implanted glucose sensors 
While the design, fabrication, and use criteria are of importance to CGM device 
use, none of these impacts the bioanalytical and clinical utility as much as the foreign 
body response (FBR). The FBR is the inflammatory response initiated by macrophages 
and foreign body giant cells, which leads to a modified wound-healing process following 
implantation of almost any medical device.37 Therefore, the development of 
biocompatible coatings is necessary to reduce this innate immune response and thus 
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improve the performance of medical devices in vivo. In general, the term “biocompatible” 
can be defined as material properties that avoid any negative local and systemic effects, 
and elicit the most appropriate local tissue response adjacent to an the implant allowing 
for improved performance.38 Along with this idea, most long-term medical implants to 
date are considered biocompatible or inert once the FBR resolves and the device is 
encapsulated by a collagen layer.39 Although CGM devices have similar circumstances, 
the combination of the FBR, oxygen and glucose availability, and need for immediate 
and frequent calibration have significantly impeded their utility and implementation as 
effective devices for diabetes management.  
1.2.1 The effect of the foreign body response on in vivo glucose sensor performance 
 Once a continuous glucose monitoring system is implanted, the host recognizes 
the sensor as foreign material and attempts to isolate the sensors as shown in Figure 
1.3.37,40 All implantable medical devices perturb the host medium, damage capillaries, 
and produce to an immune response that includes: (1) the formation of a provisional 
matrix (minutes–hours); (2) acute inflammation (days); (3) chronic inflammation (weeks); 
(4) granulation tissue formation (weeks); and, (5) fibrous capsule formation (weeks–
months).37,40 Specifically for glucose biosensors, the surface changes based on each stage 
of this immune response, cumulatively or independently affecting on sensor performance 
in vivo.  
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Figure 1.3. The foreign body response to a percutaneous glucose sensor upon 
tissue implantation. Arrows in the magnified area show diffusion of glucose form 
blood vessels toward the sensor through native tissue (e.g., adipocytes), the 
collagen capsule, localized inflammatory cells, and biofouling layer near the sensor 
surface. As illustrated, glucose may be consumed by native tissue or inflammatory 
cells prior to reaching the sensor. 
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 In the very early process of implantation, a provisional matrix instantaneously 
forms on and around foreign objects along with blood/material interactions and protein 
adhesion.19,37 The initial protein adsorption and fibrin-predominant provisional matrix is 
closely linked to the overall FBR by providing structural, biochemical, and cellular 
components for the inflammatory response.37 The chemoattractance, cytokines, growth 
factors, and other bioactive agents from the provisional matrix modulate the phenotype of 
macrophages as well as proliferation and activation of other cells.37 With this regard, the 
provisional matrix may be considered as a naturally derived membrane releasing 
bioactive agents to control subsequent phases of inflammatory response.37 In this stage, 
the adhesion of biomolecules to the sensor membrane typically results in a >50% 
decrease in the sensor response to glucose, with the greatest reduction in response caused 
by biomolecules <15 kDa.40-43 Proteomic analysis using mass spectroscopy of 
biomolecules adhered on implanted sensors in a rodent model showed both inflammatory 
cells and fragments of larger proteins infiltrated the sensor membranes and caused 
diminished glucose diffusivity.43 This protein adsorption is a time dependent process and 
mostly consists of biomolecules related to inflammatory response, including serum 
albumin, IgG, immunoglobulin, and fibrinogen.43 While this loss of sensitivity is 
reversible, the extent of signal reduction is unpredictable and requires frequent in vivo 
sensor calibration.10,41  
 As a sequential extension of provisional matrix formation, acute inflammation 
occurs through the infiltration of leukocytes, mast cell degranulation with histamine 
release, and fibrinogen adsorption.40 The biological role of the acute inflammatory 
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response is to phagocytose the foreign material. The process of macrophages digesting 
the implant may further impact in vivo sensor performance due to the local pH drop as 
low as 3.6, which may negatively affect GOx activity.44 In the acute inflammatory stage, 
the released concentrations and types of chemokines and cytokines control the extent 
and/or degree of acute inflammatory response and the subsequent development of the 
FBR based on cell recruitment and ultimate phagocytosis.45 Additionally, the activation 
state (i.e., M1 or M2) of the macrophage is an important factor that influences the overall 
FBR.46 While limited studies have demonstrated distinct surface-induced phenotypes of 
macrophages on the wound healing process, the phenotype of activated macrophages is 
considered an indicator of tissue response variable inflammatory mediators.46,47  
 Following acute inflammation, chronic inflammation occurs in a sequential 
fashion and may be identified by the presence of macrophages, monocytes, and 
lymphocytes, as well as the proliferation of blood vessels and connective tissue. This 
process initiates frustrated phagocytosis leading to the fusion of macrophages into foreign 
body giant cells (FBGCs) that attempt to further consume/degrade the implant.44,48-50 This 
effect further reduces analyte diffusion and the relative concentration of analyte in the 
localized tissue. Additionally, the consumption of oxygen and glucose by macrophages 
produces superoxide and peroxide, which for certain electrochemical sensors negatively 
impacts response (and thus accuracy).9,51 The extent of the chronic inflammatory 
response is dependent on both the physical and chemical properties of the implant, and 
the mechanical stress (i.e., due to movement) at the implant site.40 Following the 
resolution of the chronic inflammatory response, granulation tissue is formed as a 
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precursor to fibrous capsule formation due to the persistence of macrophages and 
infiltration of fibroblasts to the wound site.40  
 During the final step in the immune sequence, a fibrous capsule is formed with 
collagen surrounding the implant to isolate it completely from the local tissue 
environment.37 The collagen encapsulation (typical thickness 50–200 µm) with absence 
of the microvasculature consequently prevents implant interaction with surrounding 
native tissue.52 As such, diffusion of glucose is inhibited and the sensor fails to 
measure/report the actual blood glucose level of host. Ultimately, thick fibrous 
encapsulation significantly increases the sensor lag time, while lower subcutaneous 
vessel density and diminished capsule porosity lead to attenuation of analyte (i.e., glucose 
and oxygen) diffusion and response.53-55  
 Overall, the complex immune reaction and all stages of the FBR should be 
considered when designing outer tissue contacting membranes for implantable sensors. 
The developments of biosensor membranes that may enhance tissue integration and 
mitigate the FBR are obviously important for reducing the deleterious effects of the FBR 
on glucose sensor performance.  
1.3 Current strategies to improve biocompatibility of sensor membranes 
 Since the FBR is a complex series of events connected with various biological 
pathways, both modulating the FBR and determining its actual effect on sensor 
performance are difficult. Additionally, the chemical, physical, and morphological 
properties of an implanted materials surface can play independent and/or cumulative 
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roles on the FBR.37,38 Thus, the biocompatibility of the sensor membrane is the most 
important factor in mitigating the highly complex FBR and integrating a device into the 
surrounding tissue. This facilitates measurement of glucose with clinically relevant 
accuracy and short lag time over the lifetime of the in vivo biosensor.38 Current strategies 
for improving glucose sensor biocompatibility are grouped into two areas: active release 
and passive coatings. Active release relies on the release of pharmaceutical molecules 
that may modify the FBR and direct the wound healing process to favor tissue integration 
of the sensor. Alternatively, passive coatings rely on the modification of chemical or 
physical characteristics at the tissue-sensor interface.  
1.3.1 Active release 
In a recent initiative, implant coatings have been synthesized to release 
biologically active molecules or pharmaceutical agents to improve biocompatibility. 
Upon release from the coating to the surrounding tissue the molecules are intended to 
influence the immune response, reduce collagen encapsulation, and/or increase 
angiogenesis. Several parameters should be considered in the design of an active-
releasing surface, including the desired active molecule, toxicity, release kinetics and 
duration, relative amount, and delivery with each parameter being dependent on the 
molecule’s properties. 
Researchers have focused primarily on the local delivery of endogenous 
molecules and anti-inflammatory drugs. Since the wound-healing response is signaled in 
part by the generation of cytokines and chemokines from macrophages on the surface of 
the implant,37 release of those signaling molecules may help direct the FBR at the sensor-
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tissue interface and improve tissue integration. While many cytokines exist, vascular 
endothelial growth factor (VEGF) has been widely studied as a release reagent relevant to 
tissue-based glucose biosensors.56-62 Vascular endothelial growth factor is a cytokine 
released by macrophages and keratinocytes during wound reconstruction to promote 
angiogenesis.63-65 The expression of VEGF is induced in response to other growth factors 
and/or tissue hypoxia, with VEGF ultimately binding to tyrosine kinase receptors to 
stimulate angiogenesis.63,66 Additionally, VEGF has also been referred to as vascular 
permeability factor due to its ability to induce vascular leakage.67 However, a concern 
regarding VEGF use is an increase in local inflammation due to cell migration and 
proliferation correlated with angiogenesis.68,69 Nevertheless, the potential for greater 
capillary densities via VEGF release have led researchers to evaluate the utility of this 
strategy for improving in vivo glucose sensor performance.60 Upregulation of VEGF 
showed enhanced glucose sensor response compared to controls in a chick 
chorioallantoic membrane (CAM) model, exemplifying the usefulness of VEGF for in 
vivo biosensors.60 Additionally, surfaces that release VEGF (e.g., VEGF embedded 
poly(lactic-co-glycolic acid) (PLGA) microsphere-doped hydrogel) have shown to 
improve the vascularity of the surrounding tissue.56-62,70 Unfortunately, Ward et al. 
reported that surfaces releasing VEGF affected only a relatively small area of influence in 
subcutaneous tissue.61,62 Direct and continuous delivery of this cytokine was necessary to 
promote improved wound healing. The functional lifetime of sensors near VEGF-
releasing pumps was greater than control sensors near saline pumps.61 Additionally, the 
sensor lag time decreased and the mean absolute relative difference (MARD) for glucose 
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analysis increased, indicating sensor accuracy was improved.61 While the histological 
analysis revealed increased vascularization in tissue up to 13 mm away from the pumps, 
Clarke Error Grid analysis indicated that only sensors 1 mm from the VEGF-eluting 
pumps showed sensor accuracy improvements versus controls.61,62 This study highlighted 
the importance of the spatial release profile of angiogenic drug to improve sensor 
performance in vivo. Although recent studies indicate the potential of VEGF to influence 
the vasculature adjacent to implanted materials, the corresponding increase in 
inflammation is particularly troublesome and would likely diminish glucose sensor 
performance. 
Rather than increasing vascularity, anti-inflammatory drugs may reduce the FBR 
and represent potential active release agents from glucose sensor coatings. 
Dexamethasone (DX), an anti-inflammatory glucocorticoid steroid, is widely prescribed 
due to its ability to inhibit pro-inflammatory cytokine expression, leukocyte infiltration 
and collagen deposition.71-73 Furthermore, glucocorticoids alter inflammatory cell 
trafficking, death, and cellular responses, possibly indicating a phenotypic change in the 
cells.74 Although the exact mechanism of glucocorticoid action is not completely 
understood, the active release of DX from implants has been demonstrated to reduce 
inflammation at the implantation site.57,59,75-77 Patil et al. reported that the localized zero-
order DX release (from an implant surface) significantly diminished the acute and 
chronic inflammatory response over a 1 month period.77 The influence of DX release 
duration on FBR was also studied by Bharwaj et al. in a rodent model; they concluded 
that DX release simply delayed the immune response.78 This study clearly indicated that 
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DX must be delivered continuously (i.e., for the duration of an implant) in order to 
maintain any anti-inflammatory benefits. However, systemic use of DX can cause serious 
side effects by depressing the innate immune response, thus increasing the likelihood of 
infection.79,80 
To fully circumvent the FBR, hydrogels that release both VEGF and DX from a 
membrane were studied to reduce the inflammatory response to the implant while 
increasing angiogenesis.57,59 Unfortunately, the DX release significantly diminished the 
angiogenic benefits of VEGF.57 Other reports have also shown that glucocorticoid 
steroids, and in particular DX, inhibit VEGF activity in vivo.81-83 While concurrent 
release would be a promising approach to address the FBR as a whole, two active release 
agents that affect the FBR in a synergistic or non-antagonistic manner have yet to be 
identified.  
1.3.2 Nitric oxide-releasing membranes 
 In lieu of distinct anti-inflammatory and angiogenic agents, it may be possible to 
achieve more ideal tissue integration with nitric oxide (NO). Since NO was reported as 
the endothelial-derived relaxation factor (EDRF) in 1986,84 the role of nitric oxide in a 
variety of physiological pathways has been studied.85 Nitric oxide (NO), an endogenously 
produced diatomic molecule, plays a wide range of roles in biological process, including 
angiogenesis, wound healing, neurotransmission, smooth muscle relaxation, and 
immunoinflammation.86 These biological responses to NO are highly dependent on 
location, source, and concentration.86,87 Nitric oxide is synthesized in vivo by NO 
synthase (NOS), which catalyzes the oxidation of a guanidine nitrogen in L-arginine.86,87 
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Nitric oxide synthases exist as three isoforms: neuronal NOS (nNOS), endothelial NOS 
(eNOS), and inducible NOS (iNOS).88,89 The nNOS isoform is localized in neurons and 
skeletal muscles, and regulates synaptic signaling, muscle contractility and local blood 
flow.90 The eNOS isoform is exclusively present in the endothelium, and regulated blood 
pressure, platelet aggregation, leukocyte adherence, and vascular smooth muscle cell 
mitogenesis.91 Nitric oxide produced from the nNOS and eNOS isoforms is relatively low 
in concentration (i.e., nM). The iNOS isoform is expressed in a wide array of cells and 
tissues (e.g., macrophages and neutrophils), and becomes activated upon exposure to 
endogenous pro-inflammatory mediators and endotoxins such as lipopolysaccharide 
(LPS).92 Relatively high concentration (i.e., µM) of NO derived by iNOS involves wound 
repair and host defense in related to inflammation, infection, and diabetes.92 
 While the mechanisms of exactly how NO influences the FBR have not been 
completely elucidated, immense evidence suggests NO may increase in vivo glucose 
sensor performance by mitigating the FBR.93-95 Nitric oxide has been known as an 
angiogenic signaling molecule, up-regulating VEGF production and increasing blood 
vessel growth.96,97 This angiogenic behavior of NO may avoid the avascular collagen 
encapsulation by increasing vessel formation around implanted sensors. The improved 
blood vessel density at the site of the sensor surface may allow enhanced diffusion of 
glucose and oxygen, and thus improve glucose sensor accuracy. Additionally, the 
recruitment and activation of inflammatory cells in the early stages of the FBR relies on 
NO down-regulated pro-inflammatory cytokine expression (e.g., macrophage 
chemoattractant protein-1).95,98 Carreau et al. reported reduced leukocyte adhesion at 
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elevated NO concentrations, suggesting NO could reduce the localized inflammatory 
response at the device-tissue interface as well as mitigate the subsequent FBR.99 As such, 
NO may be able to accomplish the hypothesized actions of a dual DX/VEGF release 
while avoiding the antagonistic behavior between the drugs. Additionally, NO has a short 
half-life (<1 s in the presence of oxygen and hemoglobin) in biological milieu, arising 
from its high reactivity with transition metals, heme-containing proteins, and thiols.85,86 
Thus, NO’s sphere of influence is limited to a few µm, thus eliminating undesirable 
cytotoxicity concerns.100,101 In the presence of superoxide (O2●-), NO will react to form 
peroxynitrite (ONOO-), an even greater oxidant involved in the inflammatory response.102 
The demonstrated antibacterial activity of NO against both gram-positive and gram-
negative bacteria may also allow for a reduced risk of infection due to percutaneous 
implantation.103,104  
 Given the role of NO in the immune response and as a bactericidal agent, NO-
releasing substrates have been developed to achieve favorable tissue reactions regarding 
therapeutic applications.94 Due to the reactive nature of gaseous NO, chemical strategies 
for NO storage and release have been designed to capture NO’s pharmacological 
potential. To achieve in vivo NO release, NO donors have been employed as a method to 
store NO until breakdown of the donor upon some trigger.105,106 The most common NO 
donors include N-diazeniumdiolates and S-nitrosothiols (Figure 1.4). 
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Figure 1.4. (A) N-diazeniumdiolate and (B) S-nitrosothiol nitric oxide (NO) donors 
with decomposition pathways. Decomposition kinetics is dependent on the chemical 
structure of the NO donor, pH, temperature, and/or presence of other biological 
milieu. 
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 N-diazeniumdiolates are formed on secondary amines upon exposure to NO gas in 
basic solution.107 In the presence of a proton source (e.g., water), the N-diazeniumdiolate 
breaks down to release two molecules of NO and the amine precursor.107 The rate of NO 
release from this class of donor is highly dependent on the amine precursor structure, the 
surrounding chemical environment (e.g., hydrophobicity), and the solution condition (e.g., 
pH, ionic strength).107,108 S-nitrosothiols are formed on thiols upon reaction with 
nitrosating agents (e.g., acidified nitrite). They decompose through various mechanisms 
when exposed to light, copper (I) ion, or heat.109 The NO-release kinetics of S-
nitrosothiols are dependent on the structure of the NO donor (e.g., steric hindrance) and 
release one equivalent of NO per thiol.110 Organic molecules or macromolecules can be 
modified with both classes of NO donors to achieve targeted NO delivery. The concept of 
using NO-releasing materials for improving biocompatibility was initially investigated by 
utilizing low molecular weight (LMW) NO donors,93,111,112, including 1-[(2-
carboxylato)pyrrolidin-1-yl]]diazen-1-ium-1,2-diolate (PROLI/NO), 1-[N-(aminoethyl)-
N-(2-ammonioethyl)amino] diazen-1-ium-1,2-diolate (DETA/NO), S-nitrosoglutathione 
(GSNO), and S-nitroso-N-acetylcysteine (SNAC). Unfortunately, materials utilizing 
LMW NO donors have limited NO release durations and payloads, as well as toxicity 
concerns. Significant effort has thus focused on the synthesis of macromolecular NO 
donors to improve NO payloads, durations, and cytotoxicity.113 A number of 
macromolecular scaffolds capable of NO storage and delivery have been reported 
including xerogels,114-116 silica nanoparticles,117,118 dendrimers,119-123 micelles,124 NO 
donor-doped polymer matrices,111,125-127 and synthetic polymer.128-132  
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Nitric oxide release from macromolecular scaffolds has been shown to reduce the 
FBR in vivo. Hetrick et al. reported a reduced inflammatory response, thinner capsule 
formation, and greater blood vessel formation for NO-releasing subcutaneous implants in 
rodent model at extended periods (>3 weeks) despite only 72 h of measureable NO 
released.114 In this study, NO was released from xerogel membranes coated on medical 
grade silicone rubber. The secondary amine of N-(6-aminohexyl)aminopropyl 
trimethoxysilane (AHAP) on xerogel membrane was converted to N-diazeniumdiolates 
for NO storage resulting in NO payloads of 1.3 µmol cm-2 over 3 days.114 This level of 
NO release reduced collagen encapsulation by ~20‒25% at 3 and 6 weeks compare to 
controls. Reduced inflammatory cell adhesion near the implant was also noted with 
enhanced vascular density at 1 and 3 weeks.114 Although the NO-releasing xerogel films 
clearly showed the effect of NO on reducing the FBR, the effect of NO flux and payload 
on mitigating the FBR was not evaluated in this study. Nichols et al. reported the effect of 
NO flux on subcutaneous implants in a porcine model.133 The NO-releasing silica 
particle-doped polyurethane membranes exhibiting various NO release kinetics and 
payload (total NO released from 2.7 to 9.3 µmol/cm2 and release duration from 6 h to 2 
weeks) were coated on mock sensors and subcutaneously implanted. Although the initial 
bolus release of NO had a negative effect on the FBR (resulting in increased collagen 
density), the sustained release of NO with greater total NO release significantly reduced 
collagen capsule thickness and density.133 The results indicated a possible benefit of NO-
releasing membranes for improving in vivo glucose sensor performance.  
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 Based on the potential of NO-releasing membranes for reducing the FBR, NO-
releasing glucose sensor membranes have been developed by the Schoenfisch 
lab.125,134,135 Since the harsh procedure required to modify membrane with N-
diazeniumdiolate caused inadequate permeability of analyte, the NO-releasing glucose 
sensor membranes were fabricated by doping NO-releasing sol-gel particles in the 
polyurethane film125 or a hydrophilic polymer (i.e., poly(vinylpyrrolidone)) in NO-
releasing xerogel film,135 as well as by micro-patterning NO-releasing xerogel 
membrane.134 Of note, these NO-releasing membranes exhibited adequate analyte 
diffusion, demonstrating compatibility of NO release with enzyme-based glucose sensing. 
Additionally, the fabricated NO-releasing glucose sensors demonstrated not only 
sufficient sensor performance but also reduced bacterial adhesion holding potential to 
prevent the risk of infection during percutaneous implantation. 
 In vivo microdialysis studies were conducted by Nichols et al. in the 
subcutaneous space of rats to investigate the effects of NO on glucose recovery (i.e., 
resistance to mass transfer).136 Polyarylethersulfone (PAES) microdialysis probes were 
perfused with saturated NO solutions for 8 h per day over 2 weeks to enable consistently 
high, though intermittent, NO release (162 pmol cm-2 s-1 of NO flux).136 Using this 
methodology, zero-order NO-release kinetics were achieved with a daily total NO 
released of 4.6 µmol cm-2. After 7 d, the NO-releasing probes recovered greater glucose 
concentrations compared to controls, indicating lower resistance to mass transfer in the 
surrounding tissue. Histological analysis of the tissue surrounding the implant after 14 d 
revealed reduced capsule thickness and inflammatory cell density. The authors concluded 
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that the mitigated FBR by NO release was thus at least partially responsible for the 
superior glucose recovery.136 
 Only one in vivo report evaluating the effect of NO release on subcutaneously 
implanted electrochemical glucose sensor performance has been published. Gifford et al. 
doped (Z)-1-[N-methyl-N-[6-(N-butylammoniohexyl)amino]]-diazen-1-ium-1,2-diolate 
(DBHD/NO) (i.e., LMW NO donor) into a polyurethane/polydimethylsiloxane glucose 
sensor membrane.100 These membranes released NO with average NO flux of 7.52 
pmol·cm-2·s-1. All of the NO was released after only 18 h.100 Despite the quick depletion 
of NO, the analytical performance (i.e., sensor accuracy) of percutaneous NO-releasing 
sensors in rodent model was improved by 2.4 and 2.1% relative to controls on days 1 and 
3, respectively. Histological analysis of the tissue adjacent to the sensors showed 
decreased inflammation at 24 but not 48 h.100 Additionally, the NO-releasing glucose 
sensor exhibited a ~30 min run-in time (i.e., time required to stabilize sensor response 
after implantation), whereas a 4–10 h run-in time was observed for control sensors.100 
This work suggests that NO release may represent an important strategy for improving in 
vivo glucose sensor performance. 
1.3.3 Passive coatings 
 Passive strategies have also been sought to improve the tissue-integration ability 
of glucose biosensors.137 Since the surface chemistry at the tissue-sensor interface has a 
large influence on the activation of the immune response, research in this area has 
focused on modifying the chemical/physical properties of the outermost sensor 
surface.138,139 Coating the sensor with biomolecules is one passive strategy used to 
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circumvent the FBR, since certain materials may allow the implant to appear less foreign 
to the host. A wide range of biomolecules have been used to interact with the surrounding 
tissue and mitigate the FBR including collagen,140,141 chitosan,142 cellulose,143,144 
heparin,145 and dextran.146,147 Although these materials are still capable of eliciting an 
immunogenic response and are often undesirably biodegradable,144,148 biomolecules may 
prove beneficial for in vivo use. For example, phospholipids—a major component of cell 
membranes—has utilized as an outer layer to disguise the implant as more native than 
foreign.149 These phospholipid membranes have a high resistance to biofouling, possibly 
arising from the high water uptake of the materials.150 However, the phospholipid 
membranes have exhibited poor stability when grafted onto medical devices.151 To 
improve stability, the phospholipids have been incorporated within polymers. The 
resulting phospholipid-containing polymers have shown favorable inflammatory 
response.152,153 Kim et al. reported that macrophage adhesion to the phospholipid-
containing polymer was reduced at 3 d relative to controls; however, it was not 
significantly affected at 7, 14 and 21 d, indicating only short-term advantages in terms of 
reducing an inflammatory response.151 The general consensus is that despite the short-
term benefits, phospholipid membranes are not capable of circumventing the FBR that 
plagues sensors. 
 Rather than relying on biomolecules to improve biocompatibility, polymers can 
be designed to reduce biofouling and mitigate the FBR. Synthetic polymers have been 
used due to their ability to resist biofouling caused by protein adsorption.149 Nafion, a 
perfluorosulfonic acid-based polymer, has gathered attention as a biocompatible sensor 
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membrane.154 The utility of Nafion is further enhanced by its negative charge and 
hydrophobicity, preventing interfering species from passing through the membrane. 
Additionally, Nafion is simple to apply and is durable for short-term (<1 week) 
implantations.155,156 As an alternative to Nafion, hydrogels have also been proposed as 
outer glucose sensor membranes to enhance sensor lifetimes due to mechanical properties 
that mimic those of the surrounding subcutaneous tissue and lead to better tissue 
integration and reduced biofouling.157-160 In multiple in vivo studies, the use of hydrogel 
coatings of various compositions resulted in less fibrous encapsulation compared to non-
coated materials.159-161 Of note, Zhang et al. recently reported zwitterionic hydrogels 
implanted on subcutaneous tissue in a rodent model demonstrated almost no capsule 
formation for 3 months.162 In general when hydrogels were coupled to glucose sensors, 
the functional lifetime of the sensors was significantly increased, which was attributed to 
the improved biocompatibility at the sensor-tissue interface.159,161 Due to the tunablity of 
water uptake, hydrogels are attractive as glucose sensing platforms.157 The use of 
hydrogels has improved the linear range and reduced the oxygen dependence of glucose 
sensors due to their ability to store oxygen.27,163 While hydrogels represent a promising 
strategy to enhance long-term sensor performance, concerns pertaining to their stability 
(e.g., adherence to underlying substrates, low mechanical strength, and leaching and 
subsequent cytotoxicity of the polymer precursors) make their use problematic. In 
contrast, polyurethane (PU) has been used extensively as an outer membrane that serves 
as a biocompatible interface with the surrounding host tissue. Early studies by Zhang and 
Wilson evaluated the in vitro and in vivo performance of PU as an outer membrane, 
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exhibiting its potential as a material for glucose sensor fabrication and use.29 A number of 
studies have shown decreased collagen capsule formation and reduced FBGC adhesion 
by blending copolymers with PU (e.g., polyether PU, polycarbonate PU, and silicon 
modified PU).164-167 Biocompatibility aside, PU allows for sufficient oxygen transport 
while limiting glucose diffusion to the sensor.29 For these reasons, the outermost 
membranes of commercially available implantable glucose sensors mostly consist of 
PU.168 
 In addition to chemical composition, the physical characteristics of an implant 
surface play an important role in mitigating the FBR. In vitro tests have shown that 
surface structure affects protein169,170 and leukocyte adhesion and activation.139,171-174 
Open pore structured surfaces generally lead to a more favorable FBR in vivo.171,172 
When varied on chemically identical materials, pore size greatly influences how the host 
tissue heals around the implant. The synthesis of porous materials as biocompatible 
coatings has been achieved by sphere-templating,175 gas-foaming,176 phase-separation 
techniques,177 and electrospinning.178-180 The ideal pore size required to improve wound 
healing ranges from 5–500 µm, depending on the desired application and polymer 
composition.181 When implanted in vivo, porous materials in this size range have been 
demonstrated to promote angiogenesis and diminish fibrous encapsulation.182,183 For 
example, Marshall and coworkers reported that a hydrogel with 35 µm pore size, 
synthesized through sphere-templating, promoted angiogenesis and reduce collagen 
thickness and density in rodent subcutaneous tissue.183 The process by which different 
pore sizes mitigate the FBR has been attributed to the disruption of fibrous tissue 
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deposition while fostering vascularized cellular and tissue growth.184 Additionally, pore 
sizes of 30–40 µm may force macrophages into a reconstructive phenotype, but will not 
cause macrophages to spread or phagocytose the material.183,185 
The mechanical properties of a material also impact the resulting host response 
when implanted. External forces exerted on an implanted device can elicit an additional 
inflammatory response in the surrounding tissue.15,186 Additionally, the modulus at the 
skin-device interface must be considered. The mismatches in the elastic modulus between 
an implant and the skin that surrounds the device (e.g., sensor) can result in sheer forces 
that induce a more severe FBR.187 For example, the modulus of small fiber materials (<6 
µm) has proved critical, with lower modulus fibers (e.g., polyurethane) showing reduced 
capsule formation compared to higher modulus materials (e.g., polyethylene and 
polyester).188 This phenomenon poses a challenge in the design of percutaneous 
implanted glucose sensors because the modulii of the dermis and subcutaneous tissue fall 
in different ranges (56–260 and 0.12–23 kPa, respectively).15,189-191  
1.3.4 Electrospinning porous membrane 
Considering the aforementioned passive approaches for mitigating the FBR, 
electrospun fiber mats hold great potential as biocompatible sensor membranes among 
the available porous materials. Electrospun fibers are formed by the elongation and 
stretching of a polymer-containing liquid droplet under an electric field (typically 
between a high voltage needle and a grounded collector) when the applied electrostatic 
potential overcomes the surface tension of Taylor cone.178-180 During the flight of fibers 
to the collector, solvent evaporates and electronic charges quickly accumulate at 
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favorably oriented ends of fiber surface, repelling until the dry fiber network arrives on 
the collector.178 Electrospun fiber mats have monodisperse fiber diameters and a open 
porous structure, which can be controlled by fabrication parameters, polymer solution 
properties, and manner of collection.180 The diameter, distribution, and shape of fibers are 
mostly affected by the viscosity and conductivity of the polymer solution. Additionally, 
solvent composition, electric field, distance between needle and collector, feed rate, and 
needle size can all affect the fiber properties.178,180,192,193 The various fiber assemblies 
(e.g., such as random or aligned fibers, patterned fibers, and even three-dimensional 
fibrous architectures) can be achieved by using dynamic collection devices (e.g., rotating 
drum and parallel gap electrodes).192 The resulting fiber mats exhibit high surface area to 
volume ratios, thus enabling cell infiltration and tissue incorporation due to the porous 
structure mimicking an extra cellular membrane (ECM).171,194 Additionally, electrospun 
fiber mats have superior mechanical properties and flexibilities in surface 
functionalization compared to their non-porous analogs.180,195 Moreover, therapeutic 
molecules such as antibiotics, DNA, growth factors, and anti-inflammatory drugs can be 
encapsulated and released in a controlled fashion.195 Indeed, the electrospun fibers have 
been widely studied for biomedical applications, including wound dressings, tissue 
engineering scaffolds, and drug carriers.194-197 
Along with the advantages of electrospun fibers, the effect of fiber properties on 
the FBR in vitro and in vivo has been reported.198,199 The fiber diameter clearly 
influences the host response; small fibers (~600 nm of diameter) reduce the FBR more 
effectively than larger (>6 µm) fibers.171,200 Saino et al. reported that poly(L-lactic acid) 
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(PLLA) nano-fibers had lower in vitro macrophage activation in the early inflammation 
stage (first 24 h) than micro-fibers, indicating the importance of fiber diameter (rater than 
fiber alignment) in determining the inflammatory response.201 In contrast, Cao et al. 
reported that both alignment and orientation of the electrospun fibers greatly modulates 
the FBR in vivo; collagen capsule thickness for poly(ε-caprolactone) (PCL) fibers was 
decreased when their orientation was either aligned (~5 fold reduction) or random (~9 
fold reduction) compared to solid films made from the same polymer.171 The aligned 
fibers also demonstrated better cellular infiltration both in vivo and in vitro, while 
randomly oriented fibers exhibited distinct surface boundaries between the material and 
the fibrous capsule.171  
Although electrospun fibers indicate great promise for use as biomaterials, only 
one report has been published for implantable glucose sensor applications. Wang et al. 
recently reported the randomly oriented polyurethane electrospun fibers coated on 
needle-type glucose sensors, utilizing the porous membrane as an outermost diffusion 
controlled membrane to mitigate the FBR.202 Due to the solvent-free process of 
electrospun fiber formation, porous electrospun fibers can be coated directly onto 
enzyme-based electrochemical biosensors without compromising glucose oxidase 
activity.202 However, the development of porous glucose sensor membranes incorporating 
an active release agent has not been reported to date. 
Although drug-releasing sensor membranes have not been reported, many studies 
have demonstrated the controlled release of drugs from electrospun fibers.195,198 For 
example, Vacanti et al. reported the development of DX-releasing electrospun fibers,203 
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where dexamethasone was incorporated into PLLA and PCL electrospun fibers exhibited 
distinct release durations (~1 month and 90 min, respectively) due to intermolecular 
interactions.203 Of note, only DX-releasing PLLA fibers (i.e., longer release duration) 
significantly reduced inflammatory capsule formation compared to control PLLA and 
PCL scaffolds and DX-releasing PCL fibers.203 This research highlighted that prolonged 
release of DX from porous materials may greatly benefit biomedical applications.  
Coneski et al. reported on NO-releasing electrospun fibers.126 The LMW molecule 
(i.e., disodium 1-[2-(carboxylate)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate (PROLI/NO)) 
was doped into polyurethane and poly(vinyl chloride) solutions, and electrospun onto 
grounded disk-type collector to achieve microsized polymer fibers. The NO-release 
kinetics were controlled by the hydrophobicity of polymer with a certain concentration of 
dopant. As expected, NO release was limited due to use of the LMW NO donor. 
Nevertheless, this work set the stage for future studies aimed at longer NO-releasing 
fibers and fabrication of biosensors with fibrous sensor membranes. 
1.4 Summary of dissertation research 
My dissertation research has focused on the development of NO-releasing 
polyurethane membranes for implantable glucose biosensors. I have developed 
polyurethane films and porous membranes doped with NO-releasing scaffolds and 
evaluated the ability to fabricate needle-type glucose biosensors coated with these 
membranes. My specific aims have included:  
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1) developing controllable NO-releasing silica particle-doped polyurethane film 
membranes (i.e., release kinetics and total payload) by using polymers with 
varied water uptake and tuning the concentration of NO donor;  
2) developing NO-releasing silica particle-doped porous materials via 
electrospinning and characterizing the NO release, fiber diameter, and 
mechanical properties; 
3) fabricating needle-type implantable glucose biosensors coated with NO-
releasing dendrimer-doped porous electrospun polyurethane membranes to 
combine the most promising active and passive anti-FBR strategies; 
4) evaluating in vivo performance of the NO-releasing silica particle-doped 
polyurethane film-coated glucose biosensors in a healthy porcine model to 
study the effect of NO. 
 The goal of this introductory chapter was to provide the current status and 
ongoing challenges of continuous glucose monitoring systems, with a focus on 
percutaneously implanted electrochemical enzyme-based glucose sensors and the effect 
of the FBR on in vivo sensor performance. Additionally, this chapter covered the two 
approaches to developing biocompatible sensor membranes—active release of 
pharmaceutical agents and modification of chemical and physical membrane properties—
to mitigate the FBR. In Chapter 2, fabrication and characterization of NO-releasing 
polyurethane sensor membranes using NO donor-modified silica nanoparticles is 
described in terms of the ability to achieve controlled NO release and adequate sensor 
performance. In Chapter 3, the development of NO-releasing silica nanoparticle-doped 
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polyurethane electrospun fibers is described in terms of NO release, fiber diameter, and 
mechanical properties. Chapter 4 describes the fabrication of implantable needle-type 
glucose sensors coated with a NO-releasing porous polyurethane membrane via 
electrospinning. Characterization of the NO-releasing porous membrane coated glucose 
sensors is detailed in terms of membrane stability and sensor performance. Chapter 5 
details preliminary in vivo experiments using the NO-releasing silica particle-doped 
polyurethane membrane-coated glucose biosensors. The analytical performance of 
implanted NO-releasing glucose sensors is described with regard to the effect of NO in a 
freely moving healthy porcine model. Finally, Chapter 6 summarizes this research and 
provides future directions for expanding on this work. 
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2.1 Introduction 
Strict monitoring and control of blood glucose levels are essential for effective 
diabetes management.1 Since conventional glucose monitoring (e.g., the finger prick 
method) provides only discrete snapshots of blood glucose levels, analytical methods that 
enable continuous monitoring of glucose concentration fluctuations via implantable 
enzyme-based electrochemical sensors have been sought to improve diabetes 
management.2-4 Despite US Food and Drug Administration approval for certain devices, 
most sensors have serious shortcomings including poor accuracy, unpredictable signal 
stability, lag time in sensor response, frequent calibration requirement, and short lifetimes 
that limit their clinical utility.3,5 Undesirable sensor performance has been attributed to 
the foreign body response (FBR) and biofouling.6,7 As the outer surface of the sensor 
influences the FBR directly, recent work has focused on the development of more 
biocompatible sensor membranes to mitigate the FBR.8,9 The general consensus is that 
new strategies to improve long-
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initial inflammatory response; (2) enhance wound healing; and, (3) avoid biosensor 
degradation.10 
Due to nitric oxide’s (NO) role as an endogenous antibacterial agent,11 the 
synthesis of sol-gel-derived coatings (e.g., xerogels) capable of storing and spontaneously 
releasing NO has studied previously.12-14 These materials were shown to reduce bacterial 
adhesion,15,16 kill bacteria that did manage to adhere,17-19 and reduce in vivo infection 
rates.20 Furthermore, the NO release was shown to reduce collagen capsule thickness 
around a subcutaneous implant by >50 and ~20–25% relative to blanks and controls, 
respectively, in a rodent model.21 Concomitantly, the NO-releasing implant lessened the 
chronic inflammatory response at the tissue/implant interface by >30% and enhanced 
blood vessel formation by >77% versus controls.21 Nitric oxide-releasing sensors have 
exhibited improved biocompatibility and sensor performance.22,23 For example, Gifford et 
al. reported reduced inflammatory response for subcutaneously implanted NO-releasing 
glucose sensors over 3 d.22 In blood, Yan et al. described improved hemocompatibilty 
and in vivo sensor performance for an intravenous NO-releasing glucose/lactate sensor.23 
Additionally, the NO-releasing microdialysis probes were recently reported enhanced in 
vivo glucose recovery from during long-term (i.e., 2 weeks) implantation.24 Collectively, 
these studies indicate that NO release is a highly promising strategy that may solve the 
lingering biocompatibility problems encountered when glucose biosensors are implanted 
in vivo. 
Based on the reduced FBR as a function of NO release, combining chemistries of 
NO release with enzymatic glucose sensing to fabricate continuous glucose monitoring 
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devices has sought to improve biocompatibility and extend analytical performance. 
Although promising with respect to reduced capsule formation and implant-associated 
infection, the xerogel films resulted in unusually low glucose response when used to 
fabricate glucose biosensors.25 The glucose impermeability of the xerogel film was 
attributed to enhanced hydrolysis and condensation rates catalyzed by the aminosilanes 
and exposure to high pressures of NO (necessary to form the N-diazeniumdiolate-based 
NO donors). To address the inadequate glucose permeability, we fabricated functional 
NO-releasing glucose biosensors by patterning xerogel microarrays on top of26 or 
physically entrapping ground xerogel particles within25 standard polyurethane sensor 
membranes. These polymer configurations allowed for enhanced glucose sensitivity 
relative to sensors completely coated with xerogel films because significant potions of the 
underlying electrode surface remained unmodified by the xerogel. 
To date, a key challenge for the development of NO-releasing glucose biosensors 
has been limited NO release. While our previously published hybrid NO-releasing 
xerogel particle/polyurethane biosensor exhibited excellent analytical response 
characteristics (e.g., sensitivity, linear response, and lifetime), the NO flux and release 
duration were limited to a maximum of ~90 pmol·cm-2·s-1 for 2 d.25 The sensors 
described more recently by Gifford et al. and Yan et al. released NO with average 
maximum fluxes of 7.52 pmol·cm-2·s-1 and 40 pmol·cm-2·s-1 for 18 h and 7 d, 
respectively.22,23 As such, a void exists regarding the optimal level and duration of NO 
release required to mitigate the FBR and influence sensor performance. In this Chapter, 
the fabrication of NO-releasing glucose sensor membranes with a wide range of NO 
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fluxes (5 pmol·cm-2·s-1 to 2.5 nmol·cm-2·s-1) and release durations (16 h to 14 d) using 
NO donor-modified silica nanoparticles are described. The NO-releasing polymers are 
then used to fabricate functional glucose biosensors to further evaluate sensor response 
and stability as a function of NO release. 
2.2 Material and methods  
2.2.1 Reagents and Materials  
 Glucose oxidase (type VII from Aspergillus niger), hydrogen peroxide (30 % v/v), 
L-proline, and β-D-glucose anhydrous were purchased from Sigma (St. Louis, MO). 
Ethanol (EtOH), tetrahydrofuran (THF), and aqueous ammonium hydroxide solution 
(14.8 M) were purchased from Fisher Scientific (Pittsburgh, PA). Methyltrimethoxysilane 
(MTMOS) was purchased from Fluka (Buchs, Switzerland). N-(6-
aminohexyl)aminopropyltrimethoxysilane (AHAP3), N-(2-aminoethyl)-3-
aminopropyltrimethoxysilane (AEAP3), 3-methylaminopropyltrimethoxysilane (MAP3), 
3-mercaptopropyltrimethoxysilane (MPTMS), tetramethoxysilane (TMOS), and 
tetraethoxysilane (TEOS) were purchased from Gelest (Tullytown, PA). Tecoplast TP-
470, Tecophilic HP-93A-100, and Tecoflex SG-80A (TPU) were gifts from Thermedics 
(Woburn, MA). Hydrothane AL 25-80A (HPU) was a gift from AdvanSource 
Biomaterials Corporation (Wilmington, MA). A Griess reagent kit was purchased from 
Promega (Madison, WI). Water was purified (18.2 MΩ/cm; total organic contents <6 ppb) 
with a Milli-Q UV Gradient A10 system (Millipore Corp., Bedford, MA). Nitric oxide, 
nitric oxide calibration gas (26.4 ppm; balance N2), nitrogen and argon (Ar) gases were 
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purchased from National Welders Supply (Durham, NC). All other reagents and solvents 
were analytical-reagent grade and used as received. 
2.2.2 Preparation of NO-releasing dopant 
 1-[2-(carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate (PROLI/NO) was 
prepared by converting L-proline to NO donor form following a procedure reported by 
Saavedra et al.27 Nitric oxide-releasing silica particles were synthesized based on the sol-
gel process via the co-condensation of an aminosilane (i.e., MAP3, AEAP3, or AHAP3) 
or mercaptosilane (i.e., MPTMS) in a range of concentrations (65–75 mol%) with 
tetraethyoxysilane (TEOS) or tetramethoxysilane (TMOS) similarly to those reported in 
previous studies.28-30 Subsequent diazeniumdiolation of the amine-containing particles 
was performed under high pressure of NO for 3 d in the presence of sodium methoxide at 
room temperature. Nitrosation of the thiol-containing nanoparticles was carried out by 
reaction with acidified nitrite in the dark at 0°C. The details of the NO-releasing 
characteristics and particle sizes for each particle system are shown in Table 2.1. 
2.2.3 Hybrid sol-gel/polyurethane glucose sensor fabrication 
 A platinum macroelectrode (0.3 cm radius and 0.031 cm2 platinum surface area) 
was used to fabricate hybrid sol-gel/polyurethane glucose biosensors that consisted of 
two distinct layers: glucose oxidase and NO-releasing polyurethane. Fabrication of the 
glucose sensor was adapted from a procedure described by Shin et al.25  
  62 
  
  63 
Briefly, glucose oxidase (GOx) was immobilized within a sol-gel matrix on a polished 
platinum electrode by casting 3 µL of a GOx sol. The enzyme-containing sol was 
prepared by dissolving 9 mg of GOx into 75 µL of water and adding 50 µL of this 
solution into 25 µL MTMOS and 100 µL EtOH followed by mixing for 10 min. The NO-
releasing layer was prepared by dispersing silica particles in a polyurethane (PU) polymer 
solution consisting of 20 mg·mL-1 50% w/w TPU and HPU dissolved in 50% v/v 
THF/EtOH solution. The NO-releasing layer was formed by casting 5 µL of the resulting 
9–144 mg·mL-1 NO-releasing particles in a PU polymer solution (0.2–2.4 mg·cm-2). 
Particle concentration rather than casting volume was increased when increasing particle 
concentration per surface area. For instances where an additional polyurethane layer was 
cast on top of the NO-releasing layer, 20 µL of 20–60 mg·mL-1 polyurethane polymer 
solution dissolved in THF was used and each layer was dried under ambient conditions 
for 30 min before casting the subsequent layer.  
2.2.4 Film fabrication and methods of film study 
 Glass substrates were prepared via sonication in EtOH and subsequent UV-ozone 
cleaning for 20 min in a BioForce Tip Cleaner (Ames, IA). The NO-releasing particle-
dispersed polyurethane solution described previously was spread-cast (36.2 µL) onto a 
glass substrate (2.08 cm2). For films with an additional PU layer on the NO-releasing 
layer, PU polymer solution was cast (141 µL) in the same manner as the electrode casting 
procedure. Each layer was dried under ambient conditions for 30 min and stored in the 
dark at -20 °C under vacuum until used. This storage method was adopted to assure NO 
donor stability. Although the diazeniumdiolated particle-doped films could be stored at 
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ambient conditions (humidity 40% at room temperature) without loss of NO for 2 d, NO 
storage was sacrificed (~10%) under more humid conditions (i.e., 90% humidity, 23.7‒
25.0 °C). Nitric oxide release from NO-releasing silica particle-doped polyurethane was 
characterized using a Sievers model 280i chemiluminescence NO analyzer (Boulder, CO). 
Films were immersed in 0.01 M PBS (pH 7.4) buffer solution at 37 °C sparged with 80 
mL·min-1 nitrogen with additional nitrogen supported to the flask to match the instrument 
collection rate of 200 mL·min-1. The instrument was calibrated using 26.4 ppm NO gas 
(balanced N2) and air passed through a Sievers NO zero filter. When measuring NO from 
nitrosothiol-based materials, the sample flask was shielded from light to prevent light-
initiated NO release. Total NO release was determined spectrophotometrically by 
measuring the conversion of NO to nitrite (NO2-) using the Griess assay.31 After soaking 
NO-releasing films in PBS buffer solution at 37 °C for a period exceeding their NO 
release, 50 µL of solution was mixed with 100 µL of Griess reagent (1% w/v 
sulfanilamide in 5% v/v phosphoric acid and 0.1% w/v N-(1-
naphthyl)ethylenediaminedihydrochloride) and incubated at room temperature for 10 min. 
Absorbance of these solutions was measured at 540 nm using a Labsystem MultiskanRC 
microplate spectrophotometer (Helsinki, Finland). Total nitrite concentration was 
determined using a calibration curve constructed with a standard nitrite solution. The 
water uptake of polyurethane films was determined by measuring the mass of glass 
substrates cast with 141 µL of 40 mg·mL-1 polyurethane before/after soaking in PBS for 
3 h. The degree of silica particle leaching from the sensor membranes was assessed via 
dynamic light scattering (DLS). The NO-releasing polyurethane-coated glass substrates 
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were immersed in 2 mL PBS and incubated at 37 oC for 7 d. The concentration of silica 
particles that leached into the soak solution was determined by measuring the derived 
count rate that varied linearly with particle concentration.32,33 The derived count rate was 
then fit to a calibration curve of known particle concentrations. Film thickness was 
measured with a Tencor Alpha-Step 200 Profilometer (San Jose, CA). Half of the NO-
releasing silica particle-doped polyurethane coating was removed from the glass substrate 
and the resulting interface was probed to determine film thickness. 
2.2.5 Sensor performance of hybrid sol-gel/polyurethane glucose sensor 
 The analytical performance (i.e., sensitivity, dynamic range, and response time 
(t95%)) of the biosensors was evaluated via chronoamperometry using a CH Instruments 
1030A potentiostat (Austin, TX). All electrochemical measurements were performed in 
0.01 M PBS (pH 7.4) at room temperature using a three-electrode configuration with an 
Ag/AgCl (3.0 M KCl) reference electrode, a platinum wire counter electrode, and glucose 
biosensor as the working electrode. Glucose sensors were first hydrated in PBS for 1 h 
and polarized for 20 min to stabilize glucose response. Indeed, sensor response effects 
due to NO release and changes in membrane permeability (water uptake) were shown to 
significantly decrease during this preconditioning period (data not shown). Response and 
calibration curves were obtained by injecting 1 M glucose aliquots into 30 mL PBS at 
room temperature under constant stirring and an applied potential of +0.6 V vs. Ag/AgCl. 
25,34 Permeability (!!!) was defined electrochemically as the ratio of peak current at the 
hybrid sol-gel/polyurethane glucose sensor (∆Ix) and bare platinum electrode (∆Ib) 
response at either 0.79 mM H2O2 ( !!!!!! ) or air saturated solution ( !!!! ).34,35 
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Amperometric selectivity coefficients were calculated using equation (1),35 where ΔIGlu 
and ΔIj are the measured current values for glucose (Glu) and interfering species (j = 
ascorbic acid, uric acid, and nitrite), respectively. 
!"#!!"#,!!"# = !"# ∆!!/!!∆!!"#/!!"#                                                   (1) 
 The concentration of each interfering substance (cj) was 100 µM. The glucose 
concentration (cGlu) employed for selectivity coefficient determination was 5.6 mM. 
2.3 Results and Discussion 
2.3.1 NO-releasing glucose sensor  
 Nitric oxide-releasing glucose sensor membranes were prepared using 
polyurethanes doped with NO-releasing silica particles. These membranes were then used 
as the outermost coating for enzyme-based glucose sensors. Since NO release has 
previously been reported to increase the background current of amperometric glucose 
sensors because of the overlapping oxidation potentials of H2O2 and NO (+0.7 and +0.9 
V vs. Ag/AgCl on platinum electrode, respectively),22 an applied electrode potential of 
+0.6 V vs. Ag/AgCl was selected to monitor glucose concentration in the presence of NO 
release to avoid masking the H2O2 oxidation response at large NO fluxes (Figure 2.1). 
This potential provided the optimal combination of adequate glucose sensitivity and 
minimal current interference from NO oxidation. Glucose sensitivity was maintained 
independent of NO release from the membrane.   
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Figure 2.1. Background current of particle-doped glucose sensor with 
RSNO-modified particles (0.6 mg·cm-2) using applied potentials of (●) 
+0.80, (○) +0.65, and (■) +0.60 V vs. Ag/AgCl and with control (i.e., non-
particle-doped) PU coated sensors (□) at +0.80 V vs. Ag/AgCl. 
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For example, the normalized sensitivity of RSNO-MPTMS/TEOS particle-doped (0.6 
mg·cm-2) polyurethane-coated glucose sensors over 3 d was not altered even though the 
NO flux from the membrane was changing appreciably. Of note, a preconditioning period 
of 18 h was required with the addition of a polyurethane barrier layer to extend the linear 
response (Figure 2.2). This change may be attributed to decreased water uptake rate by 
the thicker membrane, as previously observed for other polyurethane coated glucose 
sensors. 23,36  
 The fabricated NO-releasing particle-doped membranes were characterized as 
having adequate selectivity over known interferents.4,9 For example, glucose sensors 
prepared using RSNO-MPTMS/TEOS particle-doped (0.6 mg·cm-2) polyurethane 
membranes exhibited amperometric selectivity coefficients of 0.55 ± 0.18, 0.88 ± 0.14, 
and -0.17 ± 0.13 for ascorbic acid, uric acid, and nitrite over glucose, respectively. 
2.3.2. Variation of type of NO donors 
The NO-donor systems embedded in the 50% w/w TPU/HPU polyurethane 
membranes enabled the comparison of NO release kinetics and payloads on sensor 
response. Two NO donor classes were investigated: N-diazeniumdiolates and S-
nitrosothiols. Briefly, N-diazeniumdiolates are formed on secondary amines and produce 
NO upon decomposition by protonation in aqueous solutions.29,37 Alternatively, S-
nitrosothiols (RSNO), endogenous transporters of NO, are formed on thiol precursors and 
degraded by heat, light and/or copper ions to liberate NO.38   
  69 
  
Figure 2.2. Normalized glucose sensor sensitivity by sensitivity at 3 d for the 
following sensors: (●) RSNO-MPTMS/TEOS particle-doped (0.6 mg·cm-2) glucose 
sensor; (○) non-NO-releasing particle-doped glucose sensor as a control; and (■) 
RSNO-MPTMS/TEOS particle-doped glucose sensor with an additional 
polyurethane layer (20 mg·mL-1 TPU). 
Time (h)
0 20 40 60 80
N
om
al
iz
ed
 se
ns
iti
vi
ty
 (%
)
0
20
40
60
80
100
120
140
160
180
  70 
While NO donors may be synthesized as low molecular weight compounds or larger 
macromolecules (e.g., dendrimers, and silica particles),37 the following NO-releasing 
scaffolds were chosen for study because of their low toxicity, stable nature, and wide 
range of achievable NO-release: (1) PROLI/NO, a water soluble, diazeniumdiolated low 
molecular weight compound derived from the amino acid proline; (2) three types of N-
diazeniumdiolate-modified silica particles (i.e., MAP3/TMOS, AEAP3/TMOS, and 
AHAP3/TEOS); and (3) RSNO-modified silica particles (i.e., MPTMS/TEOS). The NO 
release from N-diazeniumdiolate-modified silica particles was tuned via altering the 
structure of the aminosilane precursors. For example, MAP3 does not contain a 
stabilizing primary amine, and its decomposition rate in solution is greater than AHAP3 
or AEAP3.28,29 While both AEAP3 and AHAP3 contain a secondary and a primary amine, 
the spacing between the two amines is increased from two to six carbons resulting in 
altered diazeniumdiolate stability and ensuing NO release. The RSNO-modified silica 
particle scaffold enables more sustained NO release compared to the N-diazeniumdiolate-
modified silica particles as the decomposition is based on different mechanisms (thermal 
vs. proton).30  
Nitric oxide release from the particle-doped films was monitored in PBS (pH 7.4) 
at 37 °C to mimic physiological conditions. Corresponding NO release data for each 
system studied is provided in Table 2.2. Due to the short half-life of PROLI/NO (~1.2 
min), 99% of the stored NO (~3 µmol·cm-2) was released within the first 10 min. The 
total amount of NO delivered from PROLI/NO-doped polyurethane films was greater 
than any particle-doped system of equivalent wt% of dopant. 
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The AEAP3/TMOS particle-doped polyurethane composition released a similar 
maximum NO flux (116.1 pmol·cm-2·s-1) and total NO amount (1.70 µmol·cm-2) as 
previously reported materials shown to reduce capsule formation and the chronic 
inflammatory response.21 However, the NO release duration was limited (i.e., 20 h) and 
the NO flux was exhausted (i.e., undetectable) after 24 h. Although MAP3/TMOS and 
AHAP3/TEOS particle-doped polyurethane membranes were also characterized by 
limited NO release durations (i.e., ~15 h), their maximum NO fluxes were ~4 times larger 
than the AEAP3/TMOS particle-doped films. The MPTMS/TEOS particle-doped films 
exhibited significantly longer NO release durations (~2 weeks) representing significantly 
extended release compared to previously published NO-releasing glucose sensors.22,25 Of 
note, the maximum NO flux was 4 times larger (i.e., 426.2 pmol·cm-2·s-1) than the 
previous NO-releasing materials shown to successfully mitigate the FBR.21 The NO 
fluxes and delivery totals indicate that each type of NO-releasing sensor membrane, 
regardless of NO donor type, may hold potential for improving the biocompatibility of 
implantable glucose sensors. The multitude of NO-releasing membranes offers a wide 
range of tunability to allow for diverse NO fluxes, durations, and amounts necessary for 
future studies aimed at exploring the in vivo response of these sensors as a function of 
NO release. 
The analytical performance of the NO-releasing sensors fabricated with the above 
membranes was evaluated to assess the effects of the scaffold type and NO release on 
sensor response. 
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Similar to previously reported in vivo NO-releasing glucose sensors,22 the sensitivity and 
response time (t95%) of the fabricated sensors were found to be applicable for in vivo 
glucose sensing (e.g., ~150 nA·mM-1 and <1 min, respectively). Although the 
permeability of PROLI/NO-doped polyurethane films to H2O2 and O2 was not 
significantly different from control membranes, glucose sensitivity was decreased by 
~51%. We attribute this loss to the production of high local concentrations of NO 
affecting GOx activity.25 When larger NO-releasing scaffolds (i.e., silica particles) were 
used as dopants, glucose sensitivity decreased by ~57% and ~11% as compared to control 
(i.e., non-particle-doped) and PROLI/NO-doped membrane, respectively. The 
permeability of H2O2 through the particle-doped films also decreased by ~58% compared 
to films without particles or those doped with PROLI/NO. Perhaps related, the silica 
particle-doped polyurethane films were significantly thicker than films without particles 
or with PROLI/NO (14 vs. 2 µm thick). While larger concentrations of NO may affect 
glucose oxidase activity,25 the bulk concentration of NO released from these particle-
doped membranes (i.e., <100 µM) was not sufficient to alter the glucose oxidase activity 
as determined using an enzymatic spectroscopic assay.39 As such, the decrease in H2O2 
diffusion and glucose sensitivity most likely results from an increase in membrane 
thickness. Although RSNO particles were 7 times larger in diameter than N-
diazeniumdiolated particles (Table 2.1), the sensitivity of the resulting sensors was not 
significantly altered as a function of silica particle size. 
 Although silica is generally regarded as nontoxic,40 the stability of the NO-
releasing dopant within the polyurethane layer was investigated to further assess the 
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potential in vivo utility of these membranes. Silica particle leaching from the 
polyurethane layer into a solution mimicking physiological conditions was examined by 
soaking NO-releasing silica particle-doped polyurethane films in PBS (pH 7.4 at 37 oC). 
For all membrane compositions, the percent leaching was less than their respective limits 
of detection using DLS (<0.6% and <0.3% for N-diazeniumdiolate and RSNO-modified 
silica nanoparticle-doped films, respectively) after 7 days, regardless of the NO donor 
(Table 2.3).  
2.3.3 Variation of an additional polyurethane layer to alter NO release kinetics 
 Although NO release from RSNO-functionalized particle-doped polyurethane 
films was unaffected by the application of an additional polyurethane layer because 
temperature and not water influences RSNO decomposition (data not shown), NO release 
from N-diazeniumdiolated particle-doped polyurethane films was tunable via additional 
polymer layers to control water uptake and the resulting diazeniumdiolate decomposition. 
As shown in Table 2.4, the hydrophobic character of the polyurethane layer cast onto the 
NO-releasing layer restricted water access to the NO donor material, thus effectively 
slowing NO release. This behavior was expected based on work done previously by Frost 
et al.41 When employing Tecoplast TP-470 PU (having the lowest water uptake) as the 
outer membrane, the maximum NO flux decreased from 77.2 to 25.7 pmol·cm-2·s-1 and 
NO release duration increased from 2.5 to 189 h relative to Tecophilic HP-93A-100 PU 
(having the highest water uptake). The time to reach the maximum NO flux was also 
significantly extended from 4 min to 5 h.   
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Figure 2.3. (A) Nitric oxide flux and (B) total NO release profile from 
AEAP3/TMOS particle-doped polyurethane membranes as a function of 
additional PU layer composition (40 mg·mL-1): (●) Tecophilic HP-93A-100, (○) 
Hydrothane AL-25-80A, (■) Tecoflex SG-80A, and (□) Tecoplast TP-470. 
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 Although the extent of water uptake differed among the four types of 
hydrophobic/hydrophilic polyurethanes, NO-release character appeared to be bimodal 
(Figure 2.3). Both hydrophilic PUs (HP-93A-100 and AL-25-80A) exhibited fast NO 
release, while the more hydrophobic PUs (SG-80A and TP-470) had more sustained NO 
release. Of note, these results may be indicative of a minimum threshold of water 
diffusion (water uptake value between 0.2–0.6 mg H2O·(mg PU)-1) necessary to 
decompose diazeniumdiolates. Seemingly above/below this threshold, there is little effect 
on NO release kinetics. Both the glucose sensitivity and H2O2 permeability decreased as 
water uptake of the additional PU layer decreased (Table 2.4). However, the dynamic 
range was extended from 1–6 to 1–25 mM glucose due to reduced O2 saturation. In the 
case where the most hydrophobic polyurethane (i.e., TP-470) was used to fabricate 
sensors, little if any glucose response was achieved due to inadequate analyte 
permeability (Table 2.4). Thus, there is an inverse relationship between sustained NO 
release and achieving sufficient glucose permeability.  
 To further alter NO release from the sensor membranes, the polymer 
concentration and thus thickness of the additional polyurethane was varied. These studies 
were carried out using the Tecoflex SG-80A (TPU) polymer to balance sustained NO 
release with adequate response to glucose. As the concentration of the TPU layer was 
increased from 20 to 60 mg·mL-1 (21–46 µm thick), the NO release duration and time to 
reach the maximum NO flux both increased. As expected, the maximum NO flux was 
suppressed as the diffusion of water through the membrane decreased (Figure 2.4). At 60 
mg·mL-1 TPU, glucose response was no longer achievable (Table 2.5).  
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Figure 2.4. (A) Nitric oxide flux, and (B) NO totals from AEAP3/TMOS 
particle-doped (0.6 mg·cm-2) PU films (●) without and with additional 
Tecoflex SG-80A (TPU) layer at (○) 20, (■) 40, and (□) 60 mg·mL-1 
concentration. 
with additional PU layer
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The preparation of hydrophobic porous membranes via electrospun nanofibers doped 
with NO donors may prove to be a viable alternative for designing longer NO releasing 
glucose sensors.42 
2.3.4.  Variation of amount of silica particles doped within polyurethane film 
 Since the RSNO-modified MPTMS/TEOS particle-doped films enable the longest 
NO release duration (i.e., 14 d) with minimal silica leaching, this composition was 
chosen as a model system for studying the effect of particle concentration on NO release 
characteristics and sensor performance. As expected, the total amount and maximum flux 
of NO release were enhanced by increasing the concentration of particles doped within 
the polymer layer from 0.2 to 2.4 mg·cm-2, while the casting volume was held constant 
(corresponding to 5 µL casting volume of 9–144 mg·mL-1 particle solution) (Table 2.6). 
The associated NO release half-life from this film was ~5 h. Moreover, the film 
continued to release NO above the detection limit (i.e., 0.5 pmol·cm-2·s-1) after 14 d 
(Figure 2.5). The maximum NO flux and total NO release were ~2560 pmol·cm-2·s-1 and 
9.08 µmol·cm-2, respectively for membranes prepared using the largest particle 
concentration (2.4 mg·cm-2). Although high levels of NO release may cause apoptosis, 
NO release from the largest particle concentration doped-membrane was lower than 
levels reported to be cytotoxic or apoptosis initiating (>100 µM).43,44 Additionally, 
Hetrick et al. reported that NO-donor modified particles (70% MAP3/TEOS particles) at 
8 mg·mL-1 releasing 7.6 µmol NO mg-1 inhibited fibroblast proliferation to a lesser extent 
than clinical concentrations of currently administered antiseptics (e.g., chlorhexidine).45  
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Figure 2.5. (A) Nitric oxide flux and (B) total NO released from RSNO-
modified MPTMS/TEOS particle-doped polyurethane films as a function of 
particle concentration: (●) 0.2, (○) 0.6, (■) 1.2, and (□) 2.4 mg·cm-2. Inset of (A) 
provides enlarged view of NO flux after 7 d. 
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Nevertheless, the in vivo utility of these sensor membranes must next be assessed in an 
appropriate animal model.  
 As the concentration of the NO-releasing silica scaffold was increased, we 
observed decreased membrane stability. For example, silica particle leaching and loss of 
membrane integrity were observed for overloaded polymers, particularly when the 
particle concentration was ~7 times greater than the polymer concentration in which the 
particle were dissolved (i.e., 144 mg·mL-1 particles in 20 mg·mL-1 PU solution). In 
addition to film instability, larger dopant concentrations hindered our ability to fabricate 
homogeneous films with consistent NO release. For example, larger standard deviations 
for maximum NO fluxes were observed for the greatest particle dopant concentrations 
(Table 2.6). At greater local concentrations of NO, the buildup of NO may facilitate 
accelerated RSNO decomposition from within the films due to an autocatalytic 
decomposition mechanism.46 Film thickness increased from 5.67 to 51.63 µm upon 
increasing the particle concentration in the films from 0.2 to 2.4 mg·cm-2, respectively, 
despite keeping the casting volume constant. As a result, biosensor sensitivity was 
decreased and response time increased with larger particle concentrations due to 
decreased analyte permeability (Table 2.6). 
2.4 Conclusion 
A total NO release of ~1.35 µmol·cm-2 from an implant surface was previously 
shown to reduce the FBR.21 The total and maximum NO flux of the RSNO-modified 
MPTMS/TEOS particle-doped (0.6 mg·cm-2) films presented here are 6 times greater 
with a 4-fold longer duration. Thus, the NO-releasing particle-doped sensor membranes 
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presented here hold promise for improving the biocompatibility of in vivo glucose 
sensors and potential to improve their analytical utility. Moreover, it is clear that our 
design allows for tunable NO fluxes and delivery totals by altering: (1) the type of NO-
releasing dopant; (2) the type of polymer utilized; (3) the concentration of additional 
polymer layers; and (4) the amount of dopant in the NO-releasing layer. The glucose 
sensor performance (i.e., sensitivity, response time, and dynamic range) was affected by 
these modifications and must be evaluated and optimized for each NO-releasing 
membrane composition employed in order to fall within the clinically relevant range for 
in vivo glucose monitoring. While Hetrick et al.21 demonstrated the feasibility of a 
particular NO-releasing coating to mitigate the FBR, the materials reported here represent 
a broader range of NO donor type, polymer matrix, and NO release characteristics. 
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3.1 Introduction 
 Nitric oxide (NO) is a key physiological mediator of vasodilation, angiogenesis, 
wound healing, and phagocytosis, all of which are highly dependent on NO 
concentration.1 As many disease states and health ailments are mitigated by NO, 
exogenous NO donors are widely studied as potential therapeutic agents.2-5 In particular, 
macromolecular NO donor scaffolds have been the focus of much research due to their 
ability to store large amounts of NO and facilitate biological action. Indeed, the NO 
release achieved using xerogels,6-9 silica nanoparticles,10-12 dendrimers,13-16 biodegradable 
polyesters,17-19 and medical-grade polyurethanes20-22 has demonstrated utility to modulate 
wound healing,23,24 kill bacteria and cancer cells,25-27 and improve the analytical 
performance of chemical sensors.28-30 Silica nanoparticles modified with NO donors 
represent an attractive NO-release vehicle due to straightforward synthesis, ability to 
achieve significant NO payloads and tunable NO-release kinetics, and their inherent low 
toxicity.9,10 In Chapter 2, we employed polymers doped with NO donor-modified silica 
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particles to prepare NO-releasing glucose sensor membranes.22 Nitric oxide release from 
the sensor membranes was tuned by altering the silica particle concentration, NO donor 
type, water uptake properties of the polyurethane, and the use of an overlaying polymer 
coating of variable thickness.22 Unfortunately, the utility of these membranes for sensor 
applications was limited due to an inverse relationship between NO-release duration and 
analyte (i.e., glucose) permeability.22 A more porous NO-releasing coating is thus 
desirable to maintain adequate analyte permeability. 
 Electrospinning of polymers is a straightforward method for preparing highly 
porous materials consisting of fibers.31,32 The electrospinning process involves propelling 
an electrically charged viscoelastic jet of polymer solution to a grounded collector via a 
high voltage electrostatic field.32 As the jet of polymer solution travels through the air to 
the grounded collector, polymer nanofibers solidify upon solvent evaporation, resulting in 
a non-woven web or mat of fibers.32 Some advantages of polymeric fibers over bulk 
polymer films include large surface area to volume ratios, flexibility in surface 
functionality, and superior mechanical properties (e.g., stiffness and tensile strength).32-34 
Additionally, the microporosity of the non-woven fiber mat is believed to be ideal for 
promoting tissue integration,35,36 suggesting that these materials may be suitable as outer 
sensor membranes for subcutaneous glucose sensors.37 With physical properties that 
mimic the extracellular matrix, the use of electrospun fibers has been confirmed to 
promote cell proliferation and differentiation,35,36,38,39 enhance tissue-scaffold integration, 
and decrease fibrous encapsulation compared to bulk polymer films.39,40 Much research is 
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now focused on developing electrospun fibers as tissue engineering scaffolds, wound 
dressings, and implant and medical prostheses coatings.32-34  
 The versatility of the electrospinning process has enabled the fabrication of fiber 
mats capable of releasing silver,41-43 dexamethasone,44 and NO.18,45 With respect to NO 
release, we previously reported on polyurethane and poly(vinyl chloride) fibers capable 
of NO release by doping a low molecular weight N-diazeniumdiolate NO donor (1-[(2-
carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate or PROLI/NO) into the polymer 
solution prior to electrospinning.45 While the NO-release kinetics of the PROLI/NO-
doped fibers proved to be variable depending on the polymer composition and fiber 
diameter, the NO payloads and release durations were limited.45 The incorporation of 
macromolecular NO-release vehicles (i.e., silica particles) may enhance NO-release totals 
and durations compared to those obtained using PROLI/NO as a dopant. In this chapter, 
fabrication of macromolecular NO release scaffold-doped fibers as a function of both the 
NO-releasing particle composition and polymer fiber characteristics (e.g., diameter and 
water uptake) is described. Due to the size of the particle dopants (50–400 nm), careful 
attention is focused on the stability and mechanical properties of the ensuing fibers.  
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3.2 Experimental  
3.2.1 Materials  
 Tecoflex (SG-85A) and Tecophilic (HP-93A-100) polyurethanes were gifts from 
Thermedics (Woburn, MA). Tecoplast (TP-470) polyurethane was provided by Lubrizol 
(Cleveland, OH). The following silanes for synthesizing silica particles were purchased 
from Gelest (Morrisville, PA):  N-(6-aminohexyl)aminopropyltrimethoxysilane 
(AHAP3), N-(2-aminoethyl)-3-aminopropyltrimethoxysilane (AEAP3), 3-
mercaptopropyltrimethoxysilane (MPTMS), tetramethoxysilane (TMOS) and 
tetraethoxysilane (TEOS). All other salts and solvents were laboratory grade and 
purchased from Fisher Scientific (St. Louis, MO). Water (18.2 MΩ!cm; total organic 
content <6 ppb) was purified using a Millipore Milli-Q Gradient A-10 purification 
system (Bedford, MA).  Nitrogen, argon, and nitric oxide gases were purchased from 
Airgas National Welders Supply (Durham, NC). 
3.2.2 Synthesis of NO-releasing silica particles 
  Nitric oxide-releasing silica particles were synthesized as previously described 
via the co-condensation of an aminosilane (i.e., AEAP3 or AHAP3) or a mercaptosilane 
(i.e., MPTMS) at 65–75 mol% with a backbone silane (i.e., TEOS or TMOS).10,11,46 To 
form N-diazeniumdiolate NO donors, the amine-containing particles were exposed to 10 
atm NO gas for 3 d in the presence of sodium methoxide at room temperature with 
constant stirring in a Parr pressure vessel.46   
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S-Nitrosothiol NO donor-modified particles were prepared by treating the thiol-
containing nanoparticles with acidified nitrite for 2 h in the dark at 0 °C.11 Full 
characterization of the NO release from each particle system is provided in Table 3.1. All 
NO-releasing particle systems were stored in a vacuum-sealed, dark container at -20 °C 
until further use. 
3.2.3 Nitric oxide-releasing silica particle-doped polyurethane fiber formation.  
 Nitric oxide-releasing silica particle-doped electrospun fibers were fabricated 
using a custom electrospinning apparatus consisting of a Series 205B High Voltage 
Power Supply from Bertan Associates, Inc. (Hicksville, NY), a Kent Scientific Genie 
Plus syringe pump (Torrington, CT), and a circular steel disk (23 cm diameter) 
collector.45 Voltage was applied to a standard stainless steel blunt-tip needle (22 gauge 
and 0.508 mm ID; Jensen Global, Santa Barbara, CA) attached to a solution-filled syringe 
positioned atop the syringe pump. The grounded collector was covered in aluminum foil 
(for ease of sample collection) and mounted perpendicular to the direction of the syringe 
at a distance of 15 cm. Fiber mats were prepared by electrospinning the polymer solution 
at an applied voltage of 15 kV and a flow rate of 15 µL min-1. Resulting fiber mats were 
collected from center of disk collector for further evaluations. Polyurethane solutions 
containing NO-releasing silica particles were prepared by first dissolving the polymer in 
1.6 mL of a 3:1 (v/v) tetrahydrofuran (THF): N,N-dimethylformamide (DMF) solution, 
then mixing in a suspension of NO donor-modified silica particles dispersed in methanol 
(400 µL). The final concentration of polymer in this cocktail ranged from 8–16% (w/v) 
with particles embedded at 1–10 wt% of the polymer mass. Solution viscosity was 
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determined using a capillary-viscometer (Schott AVS 360; Hofheim, Germany) at room 
temperature. The conductivity of the polyurethane solutions was measured using a 
Malvern Nano Series Zetasizer (Malvern, England) operated in zeta potential mode, and 
consisted of an average of 5 measurements. 
3.2.4 Characterization of NO-releasing silica particle-doped electrospun fibers 
 Electrospun fibers were imaged using an environmental scanning electron 
microscope (ESEM) (Quanta 200 field emission gun; FEI company; Hillsboro, OR) with 
large-field detector (LFD) under low vacuum (i.e., 0.38 Torr). Samples were prepared 
without an additional metal coating in order to observe particles embedded in the fibers. 
Reported fiber diameters were measured with ImageJ software (NIH, Bethesda, MD) and 
reported as averages of at least 75 measurements per sample from three electrospun mats.  
 The surface area of the fiber mat was measured using a Micromeritics Tristar II 
3020 Surface Area and Porosity Analyzer (Norcross, GA). The percent porosity of the 
fiber mat was calculated according to the following equations (1) and (2).47-49 The bulk 
densities of the polyurethanes are 1.13, 1.05, and 1.18 g/cm3 for Tecophilic, Tecoflex, 
and Tecoplast, respectively. The film thickness was determined by ESEM and was found 
to be proportional to the feed volume (e.g., ~50 µm for 1 mL electrospinning solution). 
  !""!#$%&!!"#$%&'! !!"! = !"#! "##!(!)!"#!!!!"#$%&&! !" ×!"#!!"#!!(!"!)      (1) 
  !!"#!$%!!"#"$%&' = 1− !""!#$%&!!"#$%&'! !!"!!"#$!!"#$%&'!!"!!"#$%&'! !!"! ×100%      (2) 
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 The tensile strain-strength of the electrospun fiber mats was characterized using 
an Instron 5566 electromechanical tensile tester (Norwood, MA) at a cross-head speed of 
10 mm min-1. Fiber mats were cut into strips (10 mm × 29 mm) for testing and the 
thickness were determined by ESEM.50 Modulus was defined as the slope of the tensile 
stress-strain curve showing elastic deformation. The standard deviation is based on 
measurements from three different batches. Water uptake was evaluated by weighing a 
section of the fiber mat before and after soaking in PBS for 3 h.22 Leaching of silica 
particles from the fibers was evaluated by quantifying the concentration of silicon (Si) in 
solutions that the particle-doped electrospun fiber mats had been immersed (15 mL 
phosphate buffered saline (PBS) and incubated at 37 °C for 7 d). Silicon concentrations 
in the PBS soak solutions were determined using inductively coupled plasma-optical 
emission spectroscopy (ICP-OES; Teledyne Leeman labs; Hudson, NH) in an axial 
configuration at 251.611 nm. Prior to analysis, 0.05–10 ppm silica particle standard 
solutions (in PBS) were used to construct a calibration curve.  
 Nitric oxide release was measured using a Sievers chemiluminescence Nitric 
Oxide Analyzer (NOA, Model 280i; Boulder, CO). To determine NO flux, electrospun 
samples were placed in a solution of deoxygenated PBS (0.01 M, pH 7.4) at 37 °C.  
Liberated NO was carried to the NOA by continuously purging the solution and vessel 
head space with nitrogen gas at a controlled rate as previously described.11 The NOA was 
calibrated using a standard 26.80 ppm NO gas (balance nitrogen) and air passed through 
a Sievers NO zero filter. The sample vessel was shielded from light to prevent light-
initiated NO release from S-nitrosothiol-based NO donors.11 Total NO payloads were 
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determined spectrophotometrically by measuring the conversion of NO to nitrite using 
the Griess assay.51 After soaking NO-releasing fibers in PBS at 37 °C for a period 
exceeding their NO release, 50 µL of the sample solution was mixed with 50 µL of 1% 
(w/v) sulfanilamide in 5% (v/v) phosphoric acid and 0.1% (w/v) N-(1-
naphthyl)ethylenediamine dihydrochloride, and incubated at room temperature for 10 
min. The absorbance of this solution was then measured at 540 nm using a Labsystem 
Multiskan RC microplate spectrophotometer (Helsinki, Finland). Total nitrite 
concentration was determined using a calibration curve constructed with standard nitrite 
solutions. Of note, the total NO concentration measured by the Griess assay agreed with 
that obtained from chemiluminescence analysis, confirming that these materials released 
NO and not nitrite.51 
3.3 Results and Discussion 
3.3.1 Fabrication of NO-releasing silica particle-doped electrospun fiber mats 
  The therapeutic potential of active NO release from an implant surface has been 
widely discussed.3,52 The primary goal of the studies presented here was to fabricate 
stable NO-releasing silica particle-doped electrospun polyurethane fiber mats with 
porosities more apt for reducing the foreign body response when implanted 
subcutaneously,40 and thus allowing for improved analyte diffusion for sensor 
applications. Secondly, we aimed to achieve tunable NO-release properties from these 
fibers, as many of NO’s biological activities are concentration dependent.2 Three 
polyurethane compositions (i.e., Tecophilic, Tecoflex, and Tecoplast) of varying 
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hydrophobicity were chosen since water uptake of the polymer has been shown to 
influence NO release depending on NO-donor class.22 Silica particles of varied size (50‒
400 nm), NO-donor class (N-diazeniumdiolate and S-nitrosothiol), NO payload (0.4‒3.2 
µmol mg-1), and NO-release duration (9.6 h to >2 d) were employed to tune the NO-
release properties from the resulting fiber mats. Two N-diazeniumdiolated AHAP3/TEOS 
silica particle systems of different sizes (i.e., 50 and 100 nm) but similar NO-release 
properties were used to study the role of particle size on fiber mat incorporation and 
resulting NO-release. A wide range of NO-release properties was achieved by employing 
two different types of N-diazeniumdiolate-based particle systems, AEAP3/TMOS and 
AHAP3/TEOS, as well as a S-nitrosothiol-based system, MPTMS/TEOS (short, medium 
and long NO-release kinetics, respectively). Of note, the MPTMS/TEOS system was 
selected as it allowed for much longer NO release durations, despite having an altered 
composition and size relative to the AEAP3/TMOS and AHAP3/TEOS systems.11,46 
Indeed, S-nitrosothiol-modified silica particles have longer NO release duration relative 
to the N-diazeniumdiolate silica (>48 h vs. ~10 h, respectively).11 The polymer and silica 
particle concentration ranges (8–16% (w/v) and 1–10 wt%, respectively) were selected to 
allow for the greatest amount of particle incorporation within the fibers without inhibiting 
the electrospinning process. 
 As shown in Figure 3.1 and 3.2, the particles were successfully embedded inside 
of the electrospun fibers at the concentration studied with various particle and 
polyurethane types. Although the nanoparticles were not dispersed homogeneously 
within individual fibers, they were distributed throughout the entire electrospun fiber mat. 
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The electrospun polyurethane (PU) fiber mats exhibited random open porous structures 
with interconnected nano/submicron fibers and a surface area of ~2 m2 g-1. In the absence 
of silica, the percent porosities of the electrospun fiber mats were 80.3 ± 2.1, 85.8 ± 7.6, 
and 83.8 ± 3.1% for the 12% (w/v) Tecophilic, Tecoflex, and Tecoplast polyurethanes, 
respectively. Particle incorporation up to 10 wt% did not significantly influence fiber mat 
porosity. As expected based on the nature of the bulk polymer, Tecoplast fibers were 
characterized as having the lowest water uptake (0.8 ± 0.5 mg H2O/mg of PU fiber mat) 
followed by the Tecoflex (1.6 ± 0.2 mg H2O/mg of PU fiber mat), and Tecophilic (4.7 ± 
1.0 mg H2O/mg of PU fiber mat) polymers.22 The fiber mats exhibited greater water 
uptake than bulk polymer films of similar thickness after equivalent soaking time, a 
feature attributed to the open/porous structure of the fiber mats.  
 As expected, the physical properties of the electrospun fiber mats including fiber 
diameter, mechanical properties, and stability (i.e., leaching of silica particles) were 
dependent on the polymer solution concentration, polymer type, and NO donor system 
(particle type and concentration). Since porosity and fiber diameter represent important 
factors in mitigating the inflammatory response,36,39 the effects of a number of 
electrospinning parameters on fiber diameter, tensile stress-strain, and silica 
incorporation/stability of the ensuing fiber mat were determined. Varying the applied 
voltage, needle tip diameter, flow rate, and distance between the collector and needle did 
not significantly impact the fiber diameter or morphology (data not shown). In contrast, 
both the viscosity and conductivity of the polymer solution proved important for 
controlling the geometry of the fiber mat.45,53  
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Figure 3.1. Environmental scanning electron microscopy images of 12% (w/v) 
Tecoflex electrospun fibers doped with 5 wt% of N-diazeniumdiolated (A) 
AHAP3/TEOS (~50 nm), (B) AHAP3/TEOS (~100 nm), and (C) AEAP3/TMOS 
and (D) S-nitrosothiol functionalized MPTMS/TEOS silica nanoparticles.  
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Figure 3.2. Environmental scanning electron microscope images of polyurethane 
electrospun fibers composed of 5 wt% N-diazeniumdiolated-AEAP3/TMOS 
nanoparticle-doped 8% (w/v) (A) Tecophilic, (B) Tecoflex, and (C) Tecoplast; and 
12% (w/v) (D) Tecophilic, (E) Tecoflex, and (F) Tecoplast PU polymer. Scale bar 
indicates 1 µm. 
104 
Bead formation due to insufficient solution cohesion and/or improper Taylor jet 
elongation32,45,53,54 was suppressed with increasing the solution viscosity and 
conductivity.  As shown in Figure 3.2C, bead formation was only observed for fibers 
electrospun using 8% (w/v) Tecoplast polymer solutions, which exhibited a lower 
kinematic viscosity (45.3 ± 3.3 mm2 s-1) compared to Tecoflex and Tecophilic PU (67.4 ± 
1.0 and 146.6 ± 2.3 and mm2 s-1, respectively). Increasing the concentration of the 
Tecoplast polymer from 8 to 12% (w/v) increased the solution’s kinematic viscosity from 
45.3 ± 3.3 to 94.0 ± 2.2 mm2 s-1,  in turn eliminating bead formation.  
 As shown in Figure 3.3, the kinematic viscosity of the polymer solution directly 
affected the diameter of resulting fibers. For example, the average diameter of 5 wt% 
AEAP3/TMOS particle-doped 12% (w/v) PU electrospun fibers increased from 168 ± 34 
to 462 ± 109 and 551 ± 71 nm as the kinematic viscosity increased from 94.0 ± 2.2 to 
287.0 ± 1.7 and 405.8 ± 4.5 mm2 s-1 for Tecoplast, Tecoflex, and Tecophilic 
polyurethanes, respectively. Additionally, the fiber diameter of Tecophilic PU fibers was 
greater than Tecoflex and Tecoplast fibers regardless of type of dopant (Figure 3.4). 
Similarly, increasing the polyurethane concentration resulted in larger fiber diameters. 
For example, changing the concentration of Tecoflex PU in the electrospinning polymer 
cocktail from 8 to 12 and 16% (w/v) increased the size of the resulting fibers from 257 ± 
66 to 462 ± 109 and 625 ± 156 nm, respectively. The largest polymer concentration 
investigated (i.e., 16% (w/v)) inhibited proper electrospinning of Tecophilic PU due to 
needle clogging. At this concentration, the viscosity of the polymer solution as 2206.6 ± 
82.6 mm2 s-1.   
105 
  
Figure 3.3. (A) Kinematic viscosity of polymer solution and (B) diameters of resulting 
fibers from polyurethanes doped with 5 wt% N-diazeniumdiolated AEAP3/TMOS 
silica nanoparticles as a function of polymer concentration and type.  
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Figure 3.4. Diameters of 5 wt% particle-doped 12% (w/v) polyurethane 
electrospun fibers as a function of polyurethane type and NO-releasing silica 
particle dopant. Data is presented as mean ± standard deviation (n=3, >250 
measurements). 
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Such upper limit at 16% (w/v) was not observed for Tecoflex and Tecoplast as the 
polymer solution viscosities remained moderate (1576.7 ± 24.9 and 342.0 ± 3.0 mm2 s-1, 
respectively). 
 Fiber diameter was also influenced by the conductivity of the polyurethane 
solution and the type of silica particle dopants employed. The zeta potential (i.e., surface 
charge) of S-nitrosothiol-modified silica particles is low/near zero, and thus the addition 
of such particles into the polymer solution did not significantly change the solution 
conductivity. Alternatively, N-diazeniumdiolated silica particles carry a large surface 
charges due to the negatively charged NO donor group. Thus, the addition of N-
diazeniumdiolated AHAP3/TEOS and AEAP3/TMOS particles resulted in an increase in 
solution conductivity as shown in Table 3.2, which concomitantly also suppressed bead 
formation when using Tecoplast PU (Figure 3.5). Overall, the addition of N-
diazeniumdiolated AEAP3/TMOS particles reduced fiber diameter relative to undoped 
and control (non-N-diazeniumdiolated AEAP3/TMOS particle-doped) fibers because 
greater solution conductivity elevated both the charge density on the Taylor cone and the 
elongation force along the elastic jet (Table 3.2).53 Fiber diameter decreased further with 
a greater concentration of N-diazeniumdiolate particles (up to 10 wt%) for each of the PU 
systems, albeit slightly. Lastly, the fiber diameter was also influenced by the size of the 
particle dopants. Fibers prepared with 50 nm N-diazeniumdiolated AHAP3/TEOS 
particles were thinner compared to those doped with 100 nm particles (Figure 3.4). Such 
behavior is attributed to greater charge density per unit volume for polymer solution 
containing more N-diazeniumdiolated particles.  
108 
Table 3.2. Conductivity of initial polymer solution and resulting fiber diameter as a 
function of dopant type.a 
Nitric oxide donor Type of dopant Particle size 
(nm) 
Conductivity 
(µS cm-1) 
Fiber diameter 
(nm) 
None   0.9 ± 0.3 558 ± 162 
Control particle AEAP3/TMOS 152 ± 2 9.4 ± 2.2 491 ± 155 
N-diazeniumdiolate AEAP3/TMOS 152 ± 2 44.3 ± 8.2 462 ±109 
AHAP3/TEOS 56 ± 7 49.0 ± 7.5 387 ± 163 
AHAP3/TEOS 93 ± 14 48.4 ± 3.6 514 ± 190 
S-nitrosothiol MPTMS/TEOS 416 ± 23 1.8 ± 0.9 573 ± 211 
a 5 wt% particle-doped 12% (w/v) Tecoflex polyurethane electrospun fiber 
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Figure 3.5. Environmental scanning electron microscopy images of 12% (w/v) 
Tecoplast electrospun fiber mat (A) without and (B) with 5 wt% of N-
diazeniumdiolated AEAP3/TMOS particles. 
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 To assess the suitability of the PU fiber mats as biomaterials, the mechanical 
properties of the particle-doped electrospun fibers were characterized in terms of 
modulus and elongation as a function of PU type and particle concentration. For tissue-
based applications (e.g., subcutaneous implants), the mechanical properties of the 
scaffold should resemble native tissue to minimize shear stress and undesirable collagen 
deposition.55 As shown in Figure 3.6A, each type of polyurethane exhibited different 
mechanical strengths. For example, Tecoplast (12% (w/v)) fiber mats doped with 5 wt% 
AEAP3/TMOS were characterized by a modulus of 34.5 ± 18.7 MPa and elongation of 
92.3 ± 60.7% tensile strain at break, exhibiting flexible plastic-like mechanical behavior. 
The 5 wt% AEAP3/TMOS Tecophilic and Tecoflex (12% w/v) fiber mats had lower 
moduli of 1.7 ± 0.5 and 4.9 ± 0.4 MPa, respectively, and greater elongations of 223.0 ± 
32.1 and 211.52 ± 29.83 % tensile strain at break, respectively. To determine the effect of 
mechanical properties on water absorption and potential particle leaching, the tensile 
strain and stress were determined after incubating the fiber mats in PBS at 37oC for 24 h.  
The elongations of tensile strain at break were similar regardless of polyurethane. The 
tensile stress at break decreased ~50 and ~20% with wet fibers for Tecoflex and 
Tecoplast, respectively. However, the tensile stress at break increased ~100% for wet 
Tecophilic fiber mats, highlighting hydrophilic polyurethane absorbed more energy up to 
fracture. Based on these properties, the Tecoplast-based fiber mats would likely be more 
useful for prosthetic and orthopedic applications, while the Tecophilic and Tecoflex-
based fiber mats might be more suitable for pacemaker, wound dressing, and catheter 
applications.56,57 Fiber mat modulus and tensile strain were also influenced by the 
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concentration of particles incorporated into the fibers. As shown in Figure 3.6B, 
elongation of the electrospun fiber mat decreased proportionally with increasing particle 
concentration from 1 to 10 wt%. The modulus also increased with increasing particle 
dopant concentration due to decreased strength in the cross-sectional area of the load-
bearing polymer matrix.58 For example, doping AEAP3/TMOS particles into 12% (w/v) 
Tecophilic polyurethane fiber mats at a concentration of 1 wt% resulted in a modulus of 
0.9 ± 0.1 MPa, which was identical to electrospun fiber mats without additives (0.9 ± 0.2 
MPa). However, the moduli of the electrospun fiber mats increased with increasing 
particle concentration, resulting in moduli of 1.7 ± 0.5 and 2.1 ± 0.3 MPa for 5 and 10 
wt% particle concentrations, respectively. These data suggest that Tecoflex and 
Tecophilic fibers doped with low particle concentrations possess mechanical properties 
best suited for lessening the FBR at implant-tissue interfaces. 
 Although silica-based materials are generally regarded as non-toxic, leaching of 
particles from the fibers was evaluated to assess the stability of the particle-polymer 
composites. Particle-doped fiber mats were immersed in physiological media (PBS, pH 
7.4, 37 oC), and silicon content in the soak solutions was measured after 7 d to assess the 
extent of particle leaching. As expected, stability was greatly dependent on the physical 
and chemical characteristics of the particle dopants as well as the water-uptake of the 
polymers. Smaller particle dopants showed lower stability as indicated by greater 
leaching from the fiber mats (Table 3.3).   
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Figure 3.6. Tensile stress-strain curves of (A) 5 wt% AEAP3/TMOS particle-doped 
12% (w/v) electrospun fiber mats as a function of polyurethane type: Tecophilic (  ), 
Tecoflex (  ), and Tecoplast (  ), and (B) 12% (w/v) Tecophilic electrospun fiber 
mats as a control (  ) and a function of 1 (  ), 5 (  ), and 10 wt% (  ) AEAP3/TMOS 
particle concentrations. 
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Nearly all of the 50 nm AHAP3/TEOS silica particles but only 70% of the 100 nm 
particles leached from the polyurethane fibers regardless of polymer composition, 
indicating smaller particles are more readily liberated upon swelling of the fibers. 
Fortunately, the particle concentrations doped within the fibers were low, such that even 
100% leaching should not result local silica concentrations that are toxic.46,59-61 Silica 
particle leaching further decreased for all polymer compositions as the size of the particle 
dopant increased, with the largest diameter particle (MPTMS/TEOS particles at 416 ± 23 
nm) characterized by <2% leaching. Differences in polymer swelling due to water uptake 
also influenced the overall material stability. Tecoplast fibers, characterized by the lowest 
water uptake, exhibited the smallest level of particle leaching relative to the Tecophilic 
and Tecoflex polyurethanes for all dopant types. Overall, the lowest level of silica 
nanoparticle leaching (i.e., 0.7%) was achieved using the 5 wt% MPTMS/TEOS particles 
doped into 12% (w/v) Tecoplast electrospun fibers. Taken together, these data suggest 
that the greatest stability is achieved with lower water-uptake polymers and larger 
diameter particles.  
3.3.2 Nitric oxide release from silica nanoparticle-doped electrospun fiber mat 
 While our previous report on electrospun fibers demonstrated controlled NO 
release using a low molecular weight NO donor (i.e., PROLI/NO), neither the NO-release 
kinetics nor duration of release proved tunable over a wide range.45 Since optimal 
mitigation of the FBR via NO release from subcutaneous implants requires at least 48 h 
of NO release and a large overall NO payload (>1 µmol/cm2), sustained and controlled 
NO release is an important aspect in developing NO-releasing biomaterials.8,62   
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Table 3.3. Silica particle leaching from NO-releasing silica particle-doped 
polyurethane electrospun fiber mats as a function of type of polyurethane and dopant 
after 7 d soaking in PBS at 37 oC. 
NO-releasing silica nanoparticles 
(5 wt% of polyurethane mass) 
Polyurethane 
(12% (w/v) polyurethane) 
Silica particle leaching 
(%) 
AHAP3/TEOS 
(~ 50 nm) 
Tecophilic 105.8 ± 12.9 
Tecoflex 105.2 ± 10.3 
Tecoplast 97.2 ±9.7 
AHAP3/TEOS 
(~ 100 nm) 
Tecophilic 79.7 ± 5.5 
Tecoflex 84.6 ± 1.1 
Tecoplast 58.9 ± 0.3 
AEAP3/TMOS 
(~ 200 nm) 
Tecophilic 66.8 ± 14.3 
Tecoflex 39.3 ± 3.2 
Tecoplast 35.9 ± 9.2 
MPTMS/TEOS 
(~ 400 nm) 
Tecophilic 2.1 ± 0.1 
Tecoflex 0.8 ± 0.1 
Tecoplast 0.7 ± 0.1 
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 Four distinct NO-releasing silica particle systems were used to fabricate NO-
releasing fibers with diverse NO-release totals (0.4–3.2 µmol mg-1) and durations (up to 
>48 h). Since the NO-release mechanism of N-diazeniumdiolate NO donors is proton-
initiated, the NO release is generally controlled by pH and the hydrophobicity of 
surrounding matrix.22 In contrast, the NO release for S-nitrosothiol systems is not 
dependent on pH or water uptake, but rather a function of heat, light, and/or the presence 
of copper ions.11 In the case of the N-diazeniumdiolated scaffolds, both size of the 
AHAP3/TEOS particles (50 and 100 nm) had similar NO-release properties and exhibited 
larger payloads over a slightly longer release durations than the  AEAP3/TMOS particles. 
In contrast, the S-nitrosothiol-modified MPTMS/TEOS particles delivered the greatest 
NO payload (3.2 µmol mg-1) and had the longest release durations (>48 h) among all 
particle systems.  
 Analogous to the particle stability studies above, the NO release from the 
electrospun fiber mats was determined in PBS (pH 7.4) at 37 oC to mimic physiological 
conditions. Compared to previously reported PROLI/NO-doped electrospun fibers (NO-
release duration of 8 min to 1.3 h), the silica particle-doped electrospun fibers exhibited 
substantially prolonged NO release with durations ranging from 7 h to 14 d (Table 3.4). 
 Of note, the electrospinning process had no affect on the particles’ NO payload. 
For example, the total NO released from 5 wt% AHAP/TEOS particle-doped 12% (w/v) 
Tecoflex fiber mats was 98.3% of the theoretically calculated total NO (determined based 
on particle concentration in starting polymer cocktail).   
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Although the NO release from fibers doped with N-diazeniumdiolated silica particles was 
limited to <1 d, the NO fluxes from these materials may still prove useful as 
thromboresistant coatings for blood-contacting biomedical devices (e.g., stents and 
catheters) since the N-diazeniumdiolated NO donor systems release NO at fluxes required 
to promote hemocompatibilty (i.e., 0.4−5.0 pmol cm-2 s-1).63-66 As expected, longer NO-
release durations were achieved with the S-nitrosothiol-functionalized particles regardless 
of the type of polymer system employed (~2 weeks). Of note, the MPTMS/TEOS 
particle-doped electrospun fiber mats exhibited NO-release durations at or above that 
reported sufficient to mitigate the foreign body response for subcutaneous implants (i.e., 
NO release >72 h).8,62 
 The effect of polymer composition on NO-release kinetics was most apparent 
with the 50 nm N-diazeniumdiolated AHAP3/TEOS-doped electrospun fibers (Table 3.4 
and Figure 3.7). For example, 5 wt% N-diazeniumdiolate particle-doped hydrophobic 
Tecoplast fibers were characterized by the lowest maximum NO flux (3.2 ± 2.6 pmol mg-
1 s-1) and longest NO-release duration (29.9 ± 12.8 h) due to lower water uptake. The 
more hydrophilic Tecophilic-based counterparts had an increased flux and shorter release 
duration (28.0 ± 9.2 pmol mg-1 s-1 and 7.2 ± 3.6 h, respectively). The total NO release 
was constant regardless of polyurethane type as expected.   
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Figure 3.7. (A) Nitric oxide flux and (B) NO totals from 5 wt% AHAP3/TEOS (~50 
nm) particle-doped electrospun polyurethane fiber mats with 12% (w/v) of (●) 
Tecophilic, (○) Tecoflex, and (■) Tecoplast polyurethane. 
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 The NO-release kinetics proved less tunable for the larger particles systems (e.g., 
AHAP3/TEOS and AEAP/TMOS at 100 nm and 150 nm, respectively) due to the limited 
fiber diameter and decreased thickness of the water restricting layer around the particles, 
ultimately eliminating any water uptake-mediated effect on N-diazeniumdiolate NO 
donor decomposition (Figure 3.8).45 In this respect, increasing the distance water must 
diffuse through the polymer to reach the particle scaffolds may prove to be an importance 
method for fine-tuning NO-release kinetics. A future objective is to adopt a co-axial 
electrospinning strategy67 where fibers are composed of an inner layer containing the 
particle dopants and an outer shell comprised of undoped polymer of varied 
hydrophobicity and/or thickness. 
 The total NO payload and initial bolus of NO release from the fiber mats were 
further altered by changing the silica particle concentrations (Figure 3.9). As expected, 
increasing the concentration of silica particle dopant elevated both the maximum NO flux 
and total NO released from the electrospun fiber mats (Figure 3.10). For example, 
electrospun fibers doped with 1, 5, and 10 wt% AEAP3/TMOS particle concentrations 
resulted in maximum NO fluxes of 0.6 ± 0.7, 2.2 ± 1.0, and 5.4 ± 3.5 pmol mg-1 s-1, 
respectively. Additionally, the total NO released from those electrospun fibers was 3.6 ± 
3.3, 15.0 ± 5.0, and 22.3 ± 0.6 nmol mg-1 for 1, 5, and 10 wt% silica dopant 
concentrations, respectively. Similar trends were observed for all other particle 
compositions. Of importance, the greatest total NO release achieved from the particle-
doped electrospun fiber mats was lower than previously reported proven to be cytotoxic 
or cause apoptosis.68,69  
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Figure 3.8. (A) Nitric oxide flux and (B) NO totals from 5 wt% AHAP3/TEOS (~100 
nm) particle-doped electrospun polyurethane fiber mats with 12% (w/v) (●) 
Tecophilic, (○) Tecoflex, and (■) Tecoplast polyurethane. 
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Figure 3.9. Environmental scanning electron microscopy images of AEAP3/TMOS 
particle-doped 12% (w/v) Tecophilic electrospun fiber mats as a function of dopant 
concentration, (A) 1, (B) 5, and (C) 10 wt%. Scale bar indicates 5 µm. 
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Figure 3.10. (A) Nitric oxide flux and (B) NO release totals from NO donor-modified 
AEAP3/TMOS particle-doped 12% (w/v) Tecophilic electrospun polyurethane fiber 
mats as a function of dopant concentration: 1 (  ), 5 (  ), and 10 (  ) wt%.   
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Not surprisingly, neither the NO-release half-life or duration of N-diazeniumdiolated 
particle-doped electrospun fiber mats was greatly affected by the amount of particle 
dopant (1 to 10 wt%).  
3.4 Conclusion 
 The electrospun polyurethane fibers doped with NO donor-modified silica 
particles presented here have allowed us to overcome limitations of previously reported 
NO-release materials (e.g., short NO release duration and low porosity). The use of 
electrospun fibers provides a material with high porosity while maintaining mechanical 
strength compared to bulk polymers doped with NO-releasing silica particles. Moreover, 
the incorporation of NO-releasing silica particles into electrospun fibers enables greater 
NO release durations compared to electrospun fibers doped with a low molecular weight 
NO donor (1 h vs. 2 weeks). Changing the type of NO-releasing particle system, 
polyurethane water uptake, and dopant concentration resulted in a wide range of NO 
release characteristics (i.e., total NO payloads of 7.5–124.7 nmol mg-1 and durations from 
7 h to 2 weeks). Of the systems studied herein, S-nitrosothiol-modified silica particles 
promoted the longest NO release and most stable particle-fiber composites. Other 
macromolecular scaffolds, such as NO-releasing dendrimers,13-16 may also prove 
advantageous as fiber dopants as a result of  larger NO payloads that can be incorporated 
with improved polymer partitioning attributes. As a result of both flexible and open 
architectures, porous NO-releasing fibers represent ideal candidates for biomedical 
implant coatings.  
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4.1 Introduction 
 Percutaneously implanted electrochemical biosensors for continuous glucose 
monitoring (CGM) hold great potential for reducing complications of diabetes due to 
their ability to warn of hyperglycemia or hypoglycemia events.1,2 Limitations such as 
short sensor life (≤1 week), the need for frequent calibration (2‒4 times/day), and 
unreliable accuracy in the data provided have prevented wide spread use of such devices 
to date.1,3,4 Most shortcomings of CGM systems are due to the foreign body response 
(FBR).5 Inflammatory cell response and collagen capsule formation, and the risk of 
infection due to percutaneous implantation result in poor analytical performance in vivo.2 
Recent work has focused on the development of outer membranes to mitigate the FBR 
and improve tissue integration and in vivo sensor performance.2,6 
 Nitric oxide (NO)—an endogenously produced diatomic free radical—plays a 
number of physiological roles (e.g., angiogenesis, wound healing, and vasodilation) 
depending on release location and concentration.7,8 To utilize NO as a pharmaceutical 
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agent, we and others have developed macromolecular NO-release scaffolds using N-
diazeniumdiolate or S-nitrosothiol NO donors that enable controlled NO release.8,9 As 
biomaterials, NO-releasing interfaces have been shown to decrease the adhesion of 
inflammatory cell, reduce collagen capsule thickness, and increase blood vessel 
formation near the biomaterial.10,11 Additionally, the NO-releasing surfaces have proven 
to be highly effective at reducing bacteria adhesion, eradicating biofilms, and decreasing 
implant-associated infections.12-15  
 Release of NO from glucose sensor membranes has been studied as an active 
strategy to mitigate the FBR and thus improve sensor performance in vivo by addressing 
the greatest shortcoming of such devices.16 Nitric oxide release has been imparted to 
glucose sensors membranes by patterning NO-releasing xerogel array on top of a 
membrane17 or physically entrapping NO donors (e.g., NO-releasing silica particles18,19 
or low molecular weight molecules20) within polyurethane (PU) sensor membranes. Such 
NO-releasing membranes exhibited adequate analyte diffusion without compromising 
sensor performance.18,19 Gifford et al. reported that NO fluxes >0.83 pmol cm-2 s-1 for 18 
h from a needle-type glucose biosensors were sufficient to reduce inflammation and 
enhance the sensor accuracy at 24 h post implantation compared to control sensors in a 
rodent model.20  
 Surface modifications based on porous architectures have also been developed 
and represent a passive strategy for improving tissue integration and decreasing collagen 
capsule formation.21-24 Electrospun fibers appear promising as glucose sensor membranes 
because of their high surface to volume ratio and superior mechanical properties.25 
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Additionally, electrospun fibers are able to be directly coated onto electrodes without 
impeding glucose oxidase activity since the polymer fibers solidify as the solvent 
evaporates during the electrospinning process.26 Random oriented fibers with submicron 
diameter (~0.6 µm) have been reported to be effective at reducing secretion of 
proinflammatory molecules, decreasing the adhesion of foreign body giant cells, and 
promoting cell migration and proliferation—all resulting in reduced capsule 
formation.25,27-29 Wang et al. recently reported coating PU electrospun fibers on 
implantable glucose sensors using a dynamic collector, highlighting the ability to modify 
microsensors with porous membranes.26 While electrospun fibers allow for the 
encapsulation and release of therapeutics in a controlled manner,27,30,31 the use of drug-
releasing electrospun fibers for implantable glucose sensors has not yet been reported.  
 In this chapter, the design of NO-releasing dendrimer-doped electrospun PU 
fibers as porous outermost glucose sensor membranes is described. The characterizations 
of needle-type glucose biosensors fabricated using such interfaces were demonstrated the 
ability to combine both active (i.e., NO-release) and passive (i.e., porous) strategies 
within a single outer sensor membrane coating.  
4.2 Experimental  
4.2.1 Materials.  
 Glucose oxidase (type VII from Aspergillus niger), D-glucose anhydrous, 
acetaminophen (AP), L-ascorbic acid (AA), and uric acid (UA) were purchased from 
Sigma (St. Louis, MO). All salts and organic solvents were laboratory grade and 
purchased from Fisher Scientific (St. Louis, MO). Methyltrimethoxysilane (MTMOS) 
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and phenol were purchased from Fluka (Buchs, Switzerland). Tecophilic (HP-93A-100) 
and Tecoflex (SG-85A) polyurethanes were gifts from Thermedics (Woburn, MA). 
Hydrothane (AL 25-80A) polyurethane was a gift from AdvanSource Biomaterials 
Corporation (Willmington, MA). Tecoplast (TP-470) polyurethane was provided by 
Lubrizol (Cleveland, OH). Stainless steel wire (316L, 381µm diameter) was purchased 
from McMaster-Carr (Atlanta, GA). Polyterafluoroethylene (PTFE) coated-Pt/Ir (90% Pt) 
wire (177.8 µm and 246.4 µm bare and coated diameter, respectively) and silver wire (Ag 
99.99%, 127 µm diameter) were purchased from Sigmund Cohn Corp. (Mount Vernon, 
NY). Nitrogen, argon, and nitric oxide calibration gases were purchased from Airgas 
National Welders Supply (Durham, NC). Fetal bovine serum (FBS), Dulbecco's modified 
Eagle's medium (DMEM), phenazine methosulfate (PMS), 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS), 
trypsin, and penicillin streptomycin (PS) were purchased from the Aldrich Chemical 
Company (Milwaukee, WI). L929 mouse fibroblasts (ATCC #CCL-1) were purchased 
from the UNC Tissue Culture Facility (Chapel Hill, NC). Anticoagulated whole blood 
with 5 U/mL heparin was obtained from healthy pigs at the Francis Owen Blood 
Research Laboratory (Chapel Hill, NC). Serum was obtained from this sample by 
centrifuging the blood for 15 min under 2000 ×g at 4 oC. Water was purified (18.2 
MΩ·cm; total organic content <6 ppb) using a Millipore Milli-Q Gradient A-10 
purification system (Bedford, MA).  
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4.2.2 Fabrication of needle-type glucose sensors.  
 Needle-type glucose sensors were fabricated by adapting a procedure described 
previously published literatures.20,32-34 A silver/silver chloride (Ag/AgCl) wire electrode 
was fabricated by winding silver (Ag) wire on stainless steel wire (2.5 cm length). The 
wire was converted to AgCl via galvanometry by soaking in saturated ferric chloride 
(FeCl3) solution for >2 h. After sonicating in water and ethanol for 15 min each, the 
Ag/AgCl wire was removed from the stainless steel and wrapped around a 
polytetrafluoroethylene (PTFE)-coated Pt/Ir wire (3.5 cm length). A section of the PTFE 
coating (~5 mm) was then stripped from the end of wire to expose the sensing cavity. The 
end of the sensor was sealed with epoxy, resulting in a ~2 mm sensing cavity (surface 
area ~0.017 cm2). The sensing cavity consisted of four functional layers: (1) an inner-
selective membrane, that excludes electroactive interferents such as ascorbic acid (AA), 
uric acid (UA), and acetaminophen (AP); (2) a glucose oxidase layer, where glucose is 
converted to gluconolactone and oxygen to hydrogen peroxide; (3) a diffusion limiting 
layer that controls the diffusion and partitioning of glucose and oxygen to overcome the 
oxygen deficit in vivo; and, (4) a porous NO-releasing electrospun fibrous membrane 
designed to mitigate the FBR. The inner-selective polyphenol layer was applied under 
control of self-limiting electropolymerization (film thickness of ~10‒100 nm) to prevent 
interfering species from reaching or fouling the electrode surface, affording a great 
improvement in biosensor selectivity over acetaminophen in particular (Figure 4.1). The 
electrochemical polymerization of the permselective polyphenol films was carried out 
potentiostatically at +0.9 V vs. Ag/AgCl for 15 min in 40 mM phenol solution in   
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Figure 4.1. Amperometric response of 5 wt% NO-releasing dendrimer-doped 
16% (w/v) Tecoplast electrospun fiber-modified needle-type glucose sensors 
without (i) or with (ii) an inner-selective layer. Glucose and interferences 
(i.e., ascorbic acid, acetaminophen, and uric acid) were sequentially injected 
into these solutions at physiologically relevant concentrations.  
100#µm#
Acetaminophen#
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phosphate buffered saline (PBS, pH 7.4) after degassing with nitrogen for 20 min. The 
charge passed during electropolymerization was -0.53 ± 0.27 µC. A glucose oxidase 
(GOx) layer was then applied on top of the inner-selective membrane by immobilizing 
GOx within a sol-gel matrix. The enzyme-containing sol was prepared as described 
previously in Chapter 2.18,19 The needle-type electrodes were dip-coated 15 times (with a 
single cycle consisting of a 5 s dip with 10 s drying under ambient conditions). The 
enzyme layer contained an excess of glucose oxidase so that the rate of glucose 
conversion was only dependent on glucose concentration. The diffusion-limiting layer 
was added by dip-coating the electrodes twice in a polyurethane (PU) polymer solution 
consisting of 80 mg mL−1 50% (w/w) Tecoflex and Hydrothane dissolved in 50% (v/v) 
THF/EtOH solution. Each layer was dried under ambient conditions for 30 min before 
casting the subsequent layer. The thickness of the diffusion-limiting PU layer was 28.2 ± 
13.0 µm, allowing for a dynamic glucose response range over the entire physiological 
range of blood glucose concentrations (1‒30 mM). 
4.2.3 Nitric oxide-releasing dendrimer-doped polyurethane solution. 
 1,2-Epoxy-9-decene (ED) functionalized fourth-generation of poly(amidoamine) 
(PAMAM) dendrimers (PAMAM G4-ED/NO) were synthesized as previously reported.35 
Subsequent N-diazeniumdiolation of the 1,2-epoxy-9-decene (ED) functionalized fourth-
generation poly(amidoamine) (PAMAM) dendrimers (PAMAM G4-ED) was performed 
under high pressure of NO (10 atm) for 3 d in the presence of sodium methoxide at room 
temperature with constant stirring.35,36 The NO donor-modified dendrimers were then  
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Table 4.1. Nitric oxide-release properties of N-diazeniumdiolated 1,2-epoxy-9-decene 
functionalized poly(amidoamine) fourth generation dendrimers (PAMAM G4-ED/NO) in 
PBS (0.01 M, pH 7.4) at 37 oC. 
[NO]max 
(pmol mg-1s-1) 
tmax 
(min) 
Total NO released 
(µmol mg-1) 
t1/2 
(h) 
td 
(h) 
511.2 4.23 0.62 0.91 6.03 
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stored in a methanol solution with sodium methoxide at -20 °C until use. The NO-release 
properties of the dendrimers were presented in Table 4.1. 
 Polyurethane solutions containing NO-releasing dendrimers were prepared by 
first dissolving the PU in 1.6 mL of a 3:1 (v/v) tetrahydrofuran (THF):N,N-
dimethylformanide (DMF) mixture, followed by the addition of PAMAM G4-ED/NO 
solution (400 µL dissolved in methanol). The final concentration of polymer in solution 
was 12–16% (w/v). Dendrimer concentration is reported as wt% of the polymer mass.  
4.2.4 Electrospinning of the outermost glucose sensor membrane. 
 Polyurethane electrospun fiber membranes were fabricated using a custom 
electrospinning apparatus consisting of a Series 205B High Voltage Power Supply 
(Bertan Associates, Inc.; Hicksville, NY), a Kent Scientific Genie Plus syringe pump 
(Torrington, CT), and a rotating collector (Figure 4.2B).31 Voltage was applied to a 
standard stainless steel 22-gauge blunt-tip needle (0.508 mm diameter; Jensen Global, 
Santa Barbara, CA) attached to a NO-releasing dendrimer-doped PU solution-filled 
syringe positioned atop the syringe pump. A grounded collector connected with the 
fabricated glucose sensor was mounted perpendicular to the syringe at a distance of 15 
cm and rotated at a speed of 250 rpm. Fibers were prepared via electrospinning at an 
applied voltage of 15 kV using a flow rate of 15 µL min-1. The fabricated layer-by-layer 
structure of the needle-type glucose sensor is illustrated schematically in Figure 4.2A. 
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Figure 4.2. Schematics of (A) the layer-by-layer structure of NO-releasing porous 
electrospun fiber membrane coated needle-type glucose sensors with actual fabricated 
electrode shown on the right; and (B) electrospinning configuration for coating 
outermost porous membrane onto needle-type glucose sensors. 
141 
4.2.5 Characterization of NO-releasing dendrimer-doped electrospun fiber membrane. 
 Fiber diameter and percent porosity were determined using an environmental 
scanning electron microscope (ESEM; Quanta 200 field emission gun; FEI company; 
Hillsboro, OR) without additional metal coating. Fiber diameters were determined using 
NIH ImageJ software (Bethesda, MD). The percent porosity of the fibrous membrane was 
calculated according to the following equation (1), where ρ is the density of the 
electrospun fiber mats, and ρ0 is the density of the bulk polymer.23,37,38  
Porosity % = 1- ρρ0
×100%     (1) 
 Nitric oxide release was evaluated as described previously.31,39 Liberated NO was 
measured using a Sievers chemiluminescence Nitric Oxide Analyzer (NOA) Model 280i 
(Boulder, CO). To determine NO flux, electrospun samples were placed in a solution of 
deoxygenated PBS (0.01 M, pH 7.4) at 37 °C. The NO was carried to the NOA 
instrument by a stream of N2 gas at a controlled rate (200 mL min-1 instrument collection 
rate). The NOA was calibrated using a 26.80 ppm NO gas (balance N2) and air passed 
through a Sievers NO zero filter. Total amounts of NO released were determined 
indirectly by measuring the nitrite concentration via the Griess assay using a Labsystem 
Multiskan RC microplate spectrophotometer (at 540 nm; Helsinki, Finland). Of note, 
total NO concentrations measured with the Griess assay agreed with those obtained from 
chemiluminescence analysis indicating that these materials released NO and not nitrite. 
The stability and distribution of the dendrimers within the PU fibers was assessed 
using fluorometry and confocal microscopy.36 Before modifying the PAMAM 
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dendrimers with ED functional groups, dendrimers were tagged with rhodamine 
isothiocyanate (RITC) in a 1:1 molar ratio so that on average only one of the 64 primary 
amines on the dendrimer surface was modified. After fluorescently labeled dendrimer-
doped fiber membranes were incubated in PBS for 7 d at 37 oC, the fluorescence of the 
soak solution was measured using Cary Eclipse fluorescence spectrometer (Varian Inc., 
Palo Alto, CA). The fluorescence intensity represented the degree of dendrimer leaching. 
In addition to this stability test, confocal fluorescence microscopy was used to image the 
distribution of fluorescently labeled PAMAM G4-ED/NO dendrimer in the electrospun 
fibers with an LSM 510 laser scanning confocal microscope (Carl Zeiss, Thornwood, 
NY).  
4.2.6 Cytotoxicity assay.  
 In vitro cellular toxicity of blank (i.e., fibers without dendrimer), control (i.e., 
non-NO-releasing dendrimer-doped electrospun fibers), and NO-releasing electrospun 
fibers were evaluated using L929 mouse fibroblasts. The fibroblasts were cultivated in 
DMEM supplemented with 10% (v/v) fetal bovine serum and 1% (v/v) 
penicillin/streptomycin, then incubated in 5% CO2/balance air under humidified 
conditions at 37 °C. The cells were trypsinized and seeded onto tissue-culture-treated 
polystyrene 24-well plates at a density of 3 × 104 cells mL–1 after reaching 80% 
confluency. After 48 h, cells were incubated with blank, control, and NO-releasing 
electrospun fiber mats for either 24 or 48 h. Subsequently, the fiber mats were removed, 
cells were washed three times with sterile PBS, and a 1.4 mL mixture of 
DMEM/MTS/PMS (105/20/1, v/v/v) was added to each well. Once a color change was 
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observed in the blank wells, the supernatant (100 µL) from each well was transferred to a 
96-well plate prior to measuring the absorbance at 490 nm using a microplate reader 
(Thermoscientific Multiskan EX; Waltham, MA). Untreated cells were used as controls, 
and results were expressed as percent viability relative to these controls. 
4.2.7 Electrochemical sensor performance.  
 The analytical performance of the fabricated glucose biosensor was evaluated via 
constant potential amperometry using a CH Instruments 1030A potentiostat (Austin, TX). 
All electrochemical determinations were conducted in 0.01 M PBS (pH 7.4) or porcine 
serum at room temperature or 37 oC using an integrated Ag/AgCl wire as a pseudo 
counter and reference electrode. After the background current was polarized, the 
analytical performance (e.g., sensitivity, response time, and selectivity) of the sensors 
were evaluated by sequentially injecting glucose or interferent aliquots into solution with 
constant stirring and setting the working electrode to a potential of +0.6 V vs. Ag/AgCl. 
The sensitivity to glucose was determined based on the slope of the linear regression 
between the measured oxidation current and glucose concentration. The amperometric 
selectivity coefficient (!"#!!"#!"#) was calculated according to equation (2) below where 
∆Iglu and ∆Ij represent the measured current response to predetermined concentrations of 
of glucose (cglu) and interference species (cj; j=AP, AA, and UA), respectively.18 
log!!"#!"# = log!( ∆!!/!!∆!!"#/!!"#)     (2) 
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4.3 Results and Discussion 
4.3.1 Characterization of NO-releasing dendrimer-doped electrospun polyurethane 
fibers  
 Non-porous PU membranes have been employed to fabricate implantable glucose 
sensors in order to balance the diffusion ratio of glucose and oxygen, and prevent an 
oxygen deficit.20,33,40 Generally, such polymers are also considered tolerable by the body. 
Nevertheless, the immune response and subsequent collagen encapsulation that forms 
around the sensor and PU membrane still negatively impacts in vivo glucose sensor 
performance.41 To potentially reduce the foreign body response (FBR) and thus improve 
the analytical performance of CGM sensors,2,6 NO donor-containing PU fibers were 
electrospun onto enzyme-based needle-type glucose sensors as an additional outermost 
membrane on top of the standard diffusion-limiting PU layer to create a porous interface 
capable of releasing a therapeutic agent known to mitigate the FBR (Figure 4.2). 
 Prior to bench top sensor testing, the N-diazeniumdiolated dendrimer-doped 
electrospun fibrous PU membranes were characterized with respect to their physical 
properties (e.g., fiber diameter and porosity), NO release, and stability (i.e., dendrimer 
leaching). Scanning electron microscopic image of the cross section of the fully 
fabricated glucose sensor confirmed a three dimensional structure, highlighting the ability 
to successfully coat porous electrospun fibers onto needle-type microsensor. As shown 
Figure 4.3, electrospun membranes exhibited a random open pore structure with 
interconnected fibers and no bead formation over the entire electrode surface (1.4 ± 0.7 
mg/sensor) (Figure 4.3A and C).  
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Figure 4.3. Environmental scanning electron microscope (ESEM) images of (A) NO-
releasing dendrimer-doped electrospun polyurethane membrane on needle-type 
glucose sensors and (B) the cross sectional view with (i) a sol-gel/glucose oxidase 
enzyme layer, (ii) a diffusion-limiting polyurethane layer, and (iii) an electrospun fiber 
porous membrane; (C) higher magnification view of the electrospun fiber membrane 
and inset indicating distribution of fiber diameters (540 ± 139 nm); and (D) confocal 
image of a single fiber embedded with RITC-labeled dendrimer 
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Table 4.2. Characterization of NO release and glucose sensor performance for the porous 
NO-releasing electrospun fiber-modified needle-type glucose sensors as a function of the 
fiber. All porous membranes were doped with 5 wt% N-diazeniumdiolated dendrimers 
(PAMAM G4-ED/NO). 
Type of polyurethanea Tecophilic (HP-93A-100) 
Tecoflex 
(SG-80A) 
Tecoplast 
(TP-470) 
PU solution concentrationb 
(% (w/v)) 12 12 16 
Physical 
properties of 
outermost 
membrane 
Water uptake 
(mg, H2O/mg, Fiber 
mat) 
4.7 ± 1.0 1.6 ± 0.2 0.8 ± 0.5 
Percent porosity (%) 67.3 ± 4.4 57.6 ± 2.5 94.1 ± 3.7 
Fiber diameter (nm) 567 ± 288 404 ± 190 540 ± 139 
Sensor 
performance 
Glucose Sensitivity 
(nA mM-1) 4.1 ± 3.8 3.0 ± 2.0 2.4 ± 1.6 
Response time 
(t95%; s) 
32.1 ± 7.2 43.3 ± 12.7 76.4 ± 21.7 
NO release 
properties 
[NO]max 
(pmol mg-1s-1) 52.0 ± 26.1 24.4 ± 8.2 19.8 ± 6.4 
Total NO releasedc 
(µmol mg-1) 0.15 ± 0.02 0.14 ± 0.03 0.10 ± 0.01 
td (h) 7.3 ± 3.6 8.9 ± 1.6 6.7 ± 1.0 
a The water uptake of polyurethanes was described previously.18 
b Concentration of polymer solution was optimized to achieve 400–600 nm fiber.28 
c Total NO released as determined using the Griess assay. 
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 Water uptake by the fabricated fibers, important for both glucose response and 
NO release, varied based on the type of PU (4.7 ± 1.0, 1.6 ± 0.2, and 0.8 ± 0.5 mg of 
water/mg of PU fiber for Tecophilic, Tecoflex and Tecoplast, respectively). Fiber 
diameters ranging from 400-600 nm were achieved by varying the concentration of PU 
solution (12–16% (w/v)). Of note, such diameters were previously shown to reduce both 
the adhesion and activation of macrophage cells, suggesting a lessened initial FBR.28  
The presence of the NO donor-modified dendrimer did not significantly affect fiber 
diameter. The percent porosity of the fibrous membranes for fiber diameters ranging from 
400-600 nm was 67.3 ± 4.4, 57.6 ± 2.5, and 94.1 ± 3.7 % for the Tecophilic, Tecoflex, 
and Tecoplast fibers, respectively. Such porosity is in line with prior reports describing 
the use of highly porous interfaces (>90% porosity) to increase cell infiltration and 
reduce collagen capsule formation (i.e., thickness).23, 29 Based on the above data and the 
prior tissue biocompatibility literature, the Tecoplast fiber mat would likely be most 
effective at reducing the FBR.  
 Nitric oxide release from PAMAM G4-ED/NO dendrimer-doped electrospun 
fiber membranes was measured in PBS (pH 7.4) at 37 oC to mimic physiological 
conditions (Figure 4.4). The Tecoplast electrospun fiber membrane doped with 5 wt% 
PAMAM G4-ED/NO dendrimer exhibited a maximum NO flux of 19.8 ± 6.4 pmol mg-1 
s-1 with 0.10 ± 0.08 µmol mg-1 total NO released over ~7 h. The time to reach maximum 
NO flux was 2.2 ± 0.3 min.  
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Figure 4.4. Nitric oxide flux and total NO release from 5 wt% PAMAM 
G4-ED/NO dendrimer-doped 16% (w/v) Tecoplast electrospun 
polyurethane fiber membranes.!
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 As expected, the total NO released was proportional to the amount of dendrimer 
embedded within the fibers. For example, the total amount of NO released from the 
Tecoplast PU fibers was increased from 0.10 ± 0.08 to 0.27 ± 0.12 µmol mg-1 upon 
altering the NO donor (PAMAM G4-ED/NO) concentration from 5 to 10 wt%. 
Surprisingly, the NO-release kinetics were not altered based on water uptake by the PU. 
Although the use of more hydrophobic PU (i.e., Tecoplast) resulted in a slightly 
suppressed maximum NO flux, the duration of NO release was similar to the NO-
releasing dendrimer alone (Table 4.2). Such behavior is attributed to the porous structure 
of the electrospun fiber mat and/or the distribution of dendrimers within the fibers 
(Figure 4.3D).31 Based on the most ideal characteristics (i.e., fiber diameter, porosity, and 
NO release), the Tecoplast fiber mat was chosen for further study. 
 Rhodamine isothiocyante (RITC) fluorophore-tagged dendrimers were used to 
evaluate the distribution and stability of NO donor. As indicated in the confocal 
microscopy images of Figure 4.3D, fluorescent NO-releasing PAMAM G4-ED 
dendrimers were homogeneously dispersed both within individual fibers and throughout 
the entire fiber mat. Stability of the NO-releasing dendrimer within the fibers was 
determined using a leaching assay. Fibers doped with fluorescently tagged dendrimers 
were immersed in PBS (pH 7.4 at 37 oC) for 7 d. Fluorescence emission (at 570 nm) of 
the soak solution was then measured using fluorometer. These soak solution did not 
fluorescence, indicating negligible leaching (<0.5%) of the dendrimer NO-releasing 
vehicles from the fibers.  
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Figure 4.5. Relative viability of L929 mouse fibroblasts to polyurethane electrospun 
fibers without (blank) and with dopant: non-NO-releasing dendrimer (control) and 
NO-releasing dendrimer (i.e., PAMAM G4-ED/NO) for 24 and 48 h. 
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While minimal leaching limits the dendrimer-related toxicity concerns, 
cytotoxicity of the electrospun fibers was evaluated for future applications. A cytotoxicity 
assays (i.e., MTS assay) was performed using L929 mouse fibroblasts over 48 h to 
evaluate the toxicity of the electrospun fiber mats. The normalized cell viabilities, as a 
function of fiber mat type, after 24 and 48 h are given in Figure 4.5. The Tecoplast 
polyurethane fibers without dendrimer dopants (i.e., blank) were demonstrated no loss in 
cell viability, whereas the addition of non-NO-releasing dendrimers (i.e., control) 
decreased average cell viability to 50–60% despite the absence of dendrimer leaching 
from the fibers. This decrease in cell viability may be attributed to the distribution of 
dendrimer throughout the entire fiber, allowing some functional group to become in 
contact with the cells. However, NO-release from fibers improved fibroblast viability, 
with a ~20% improvement was observed upon the incorporation of NO release (85 ± 14 
and 68 ± 13% viability at 24 and 48 h, respectively). Such a decrease in cytotoxicity for 
the NO-releasing fibers at 48 h was unexpected given the short duration of NO release 
(6.7 ± 1.0 h), but suggests that extended release durations may further improve the 
biocompatibility of such fibers in vitro. 
 To assess the structured stability of the three-dimensional porous membranes, the 
electrospun fiber-coated glucose sensors were soaked in porcine serum for 7 d at 37 oC. 
As shown in the ESEM images in Figure 4.6B, the topography of the Tecoplast 
electrospun fiber mat-modified sensor was constant even after 1 week incubation in 
porcine serum.   
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Figure 4.6. Environmental scanning electron microscope (ESEM) images of the 
sensor surface without porous membrane (A) and with NO-releasing dendrimer-
doped outermost electrospun fiber membrane (B) incubated in porcine serum for 7 d. 
Inset shows an enlarged view of B.#
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While protein adhesion, a primary cause of erratic sensor response in vivo,42 was 
observed on the non-porous sensor surface (Figure 4.6A), no significant protein 
adsorption was observed on or beneath the electrospun fiber membranes. Of note, the 
structural stability and reduced protein adsorption on the porous membranes suggests a 
potential to improve tissue integration and sensitivity in vivo.43  
4.3.2 Electrochemical performance of electrospun membrane coated glucose biosensor. 
The analytical response of the fabricated NO-releasing electrospun fiber-modified 
needle-type glucose sensors was characterized in vitro as a function of PU composition to 
assess the impact of the fiber mat. Neither the electrospinning process nor NO release 
affected the sensor performance (Figure 4.8).18,26 
Sensor response was studied as a function of the electrospun membrane thickness 
using the most hydrophobic PU (i.e., Tecoplast). Fiber mat thickness was varied by 
adjusting the feed volume of the polymer solution during the electrospinning process. 
Greater feed volumes resulted in thicker fiber mats (44.5 ± 12.2, 71.5 ± 19.1, and 241.5 ± 
84.3 µm for 1, 2, and 3 mL, respectively) that were no longer useful as sensor membranes 
(Figure 4.7). While the addition of electrospun fiber membranes ≤50 µm thick responded 
rapidly (~1 min response time (t95%)) to changes in glucose concentrations, thicker (>50 
µm) fiber mat membranes exhibited response times similar to non-porous hydrophobic 
PU sensor membranes (t95%= ~125–250 s). Subsequent sensor performance testing was 
thus carried out using biosensors fabricated with thin (~45 µm) electrospun fiber mat 
membranes. 
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Figure 4.7. Amperometric response of needle-type glucose sensors coated with 
NO-releasing dendrimer (PAMAM G4-ED/NO)-doped membranes at a fiber mat 
thickness of (i) 45 to (ii) 72 and (iii) 242 µm. The glucose concentration was 
changed at 3 mM increments. 
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Figure 4.8. (A) Amperometric response of a needle-type glucose sensor for (i) control 
(i.e., without) and (ii) 5 wt% NO-releasing dendrimer-doped 16% (w/v) Tecoplast 
electrospun fiber-modified outermost membrane. Glucose, ascorbic acid (AA), 
acetaminophen (AP), and uric acid (UA) were sequentially injected at relevant in vivo 
concentrations. (B) Calibration curves of (i) control and (ii) porous electrospun fiber 
membrane-modified glucose sensors in pH 7.4 PBS. The applied electrode potential 
was +0.6 V vs. Ag/AgCl. 
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Glucose sensor performance was also evaluated as a function of PU fiber 
composition and water uptake. Regardless of PU fiber composition, the dynamic 
response range of all sensors was 1–30 mM glucose due to the diffusion-limiting full PU 
membrane layer beneath the porous fiber mat. The use of lower water uptake PU (i.e., 
Tecoplast) resulted in decreased sensor response to changing glucose concentrations and 
longer response time (Table 4.2). While Tecophilic PU had a negligible effect on 
sensitivity and response time, the more hydrophobic PU (i.e., Tecoplast) reduced sensor 
response to glucose by ~30% while increasing response time (t95%) from 15.9 ± 9.0 to 
76.4 ± 21.7 s. The addition of the more hydrophobic porous membrane neither 
compromised the selectivity nor dynamic range (Figure 4.8). Despite the diminished 
sensor performance, the sensitivity of the resulting glucose biosensor coated with the 
dendrimer-doped Tecoplast (16% (w/v) electrospun fiber with 5 wt% PAMAM G4-
ED/NO dendrimer) was 2.4 ± 1.6 nA/mM (Figure 4.8), a response comparable to 
commercially available and previously published implantable glucose biosensors.40,44 The 
amperometric selectivity coefficients of the biosensors were -0.73 ± 0.85, 0.96 ± 0.10, 
and 0.28 ± 0.14 for ascorbic acid, acetaminophen, and uric acid, respectively, indicating 
that the fiber mat-modified biosensors were adequately selective for glucose over 
interferences at physiologically relevant concentrations. Finally, the sensor response in a 
porcine serum solution was characterized to mimic a more physiologically relevant 
solution. The sensitivity of the NO-releasing sensors in porcine serum at 37 oC was 2.15 
± 0.60 nA/mM (data not shown). In addition, the biosensors remained functional for at 
least a week in serum. While bench top evaluation of sensor performance suggests a 
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viable device, in vivo experiments are obviously necessary to understand and benefit of 
porosity and NO release on analytical performance. 
4.4 Conclusion 
Porous fiber mats capable of NO release may reduce the undesirable FBR 
associated with sensor implantation in subcutaneous tissue. Herein, a facile 
electrospinning method was developed to modify needle-type electrochemical biosensors 
with thin, NO-releasing PU fiber mat membranes. Importantly, sensor performance was 
not diminished with the additional NO-releasing membrane, suggesting similar fibrous 
coatings could be applied to other tissue-contacting devices with minimal impact to 
device utility.  
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CHAPTER 5: IN VIVO PERFORMANCE OF PERCUTANEOUSLY 
IMPLANTED NITRIC OXIDE-RELEASING GLUCOSE SENSORS IN A 
FREELY MOVING PORCINE MODEL 
 
5.1 Introduction 
 Continuous glucose monitoring (CGM) devices based on electrochemical real-
time measurement represents a pivotal technology for enabling tight control of blood 
glucose levels and preventing complications associated with diabetes.1,2 Indeed, the 
integration of an implantable glucose sensor with an insulin pump holds significant 
promise in the development of an artificial pancreas.2 Although the concept of an 
implantable electrochemical glucose sensor was introduced in the early 1990s, most 
GCM systems to date have been met with limited success.2 Shortcomings of current 
CGM technology including limited sensor lifetime, unpredictable sensor performance, 
and inaccurate measurement are mainly caused by the foreign body response (FBR).3,4 
Therefore, significant research efforts have focused on the development of more 
biocompatible sensor membranes that mitigate the FBR.  
 Membranes that release pharmaceutical agents have been explored as a method to 
promote angiogenesis and suppress inflammation at the sensor surface.5,6 To this end, 
nitric oxide (NO) become a focus due to its wide range of biological roles (e.g., wound 
healing, anti-inflammatory, and angiogenesis).7,8 To utilize NO therapeutically, 
macromolecules that store and deliver NO have been developed to overcome NO’s highly 
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reactive nature.9 Many NO-release vehicles have been synthesized by modifying 
polymeric scaffolds (e.g., xerogels10,11 and silica nanoparticles12-14) with two common 
NO donors: N-diazeniumdiolates and S-nitrosothiols. To assess the effect of NO on the 
FBR, Hetrick et al. examined the tissue response of subcutaneously implanted N-
diazeniumdiolated xerogel membranes in a rodent model.11 The NO-releasing implants 
(~1.35 µmol NO/cm2 released over 72 h) reduced the associated collagen capsule 
thickness by >50% and up to 20‒25% after 3 weeks (even when the NO release was 
expired) versus blank and control implants, respectively. Additionally, blood vessel 
formation was improved by ~77% compared to controls after 1 week implantation. With 
this initial study indicated the ability of NO to reduce the FBR, Nichols et al. studied on 
the effects of NO-release kinetics and totals on the FBR to subcutaneous implants in a 
porcine model.15 In this study, NO-releasing silica nanoparticle-doped polyurethane 
membranes were utilized to further vary the NO-release properties (NO totals and 
durations of 2.7–9.3 µmol/cm2 and 6 h to 2 weeks, respectively). Histological analysis 
revealed that increased NO-release durations and greater NO payloads significantly 
reduced collagen encapsulation at both 3 and 6 weeks, suggesting prolonged NO release 
may be key for mitigating the FBR.  
 To facilitate the ability of NO release to impact inflammation and wound healing, 
we designed NO-releasing membrane-coated implantable glucose sensors. Shin et al. 
described the development of NO-releasing xerogel sensor membranes to enhance 
biocompatibility while maintaining clinically relevant sensor performance.16 
Unfortunately, the N-diazeniumdiolate xerogel membranes exhibited poor analyte 
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permeability due to the process required to form the NO donor (i.e., exposure to high 
pressures of NO). To avoid this problem, these membranes were grounded and embedded 
into the polyurethane sensor membranes.16 Glucose sensors coated with these hybrid 
membranes exhibited adequate sensor performance, demonstrating for the first time the 
ability to combine NO chemistry with an electrochemical glucose biosensor.16 
Additionally, NO-releasing poly(vinylpyrrolidone)-doped xerogel membranes17 and 
micropatterned xerogel membranes18 were designed to improve the permeability of both 
hydrogen peroxide and glucose using more conventional film-based technology. Glucose 
sensors coated with these membranes both allowed for glucose detection and reduced 
bacterial adhesion.17,18 However, this work stopped short of in vivo testing of any 
analytical performance enhancements. 
 Gifford et al. published the first in vivo evaluation of an NO-releasing glucose 
sensor in a rodent model.19 A polyurethane membrane doped with a low molecular 
weight N-diazeniumdiolated molecule (i.e., (Z)-1-[N-methyl-N-[6-(N-
butylammoniohexyl)amino]]-diazen-1-ium-1,2-diolate (DBHD/NO)) was coated onto 
needle-type glucose sensors. The sensors released ~5 pmol cm-2 s-1 of NO for at least 12 
h and met established analytical criteria for implantable glucose sensors (e.g., sensitivity 
of ~4 nA/mM for both NO-releasing and control sensors).19,20 Along with a histological 
evaluation demonstrating a significant reduction in the initial inflammatory response, the 
NO-releasing glucose sensors yielded 99.7% of the glucose determinations within zones 
A and B of the Clarke Error Grid (clinically accurate and acceptable zones, respectively) 
on the first day of implantation. Although the short-term (i.e., <3 d) benefit of the NO-
!! 166 
releasing sensor was reported, an extended implantation period with prolonged NO 
release from membrane-coated sensors would be necessary to elucidate any FBR 
improvement in analytical performance of the NO-releasing sensor membranes. 
Additionally, a porcine model may be a more relevant animal model due to the 
physiological and anatomical similarities between pigs and humans.21 Indeed, the 
development of glucose sensor membrane with prolonged (>24 h) NO release in a 
porcine model is necessary to fully demonstrate any sensor performance improvement 
related to NO. 
 In this chapter, the in vivo performance of needle-type glucose biosensors coated 
with S-nitrosothiol-modified silica nanoparticle-doped polyurethane is described to assess 
the effect of NO on sensor performance. This membrane released ~1.3 µmol NO/cm2 for 
24 h with the NO flux detectable via chemiluminescence NO analyzer, a similar level to 
that previously shown to reduce collagen capsule.11,15 The analytical performance of the 
NO-releasing sensors was evaluated according to an in vivo numerical accuracy test and 
compared to controls. 
5.2 Methods and materials 
5.2.1 Materials 
 All materials and solvents were analytical grade and used as received. 3-
Mercaptopropyltrimethoxysilane (MPTMS) and tetraethoxysilane (TEOS) were 
purchased from Gelast (Tullytown, PA). Ethanol (EtOH) and tetrahydrofuran (THF) were 
purchased from Fisher Scientific (Fair Lawn, NJ). The Tecoflex (SG-85A) polyurethane 
was a gift from Thermedics (Woburn, MA). The Hydrothane (AL 25-80A) polyurethane 
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was a gift from AdvanSource Biomaterials Corporation (Willmington, MA). CIDEX 
PLUS® 28 Day Solution was purchased from Johnson and Johnson (Irvine, CA). 
Phosphate buffered saline (PBS; 0.01 M, pH 7.4) was autoclaved and stored at room 
temperature in a sterilized hood. Biological fluids were collected from anticoagulated 
whole blood (5 U/mL heparin) obtained from healthy pigs at the Francis Owen Blood 
Research Laboratory (Chapel Hill, NC).22 Platelet rich plasma (PRP) was collected as the 
supernatant by centrifuging anticoagulated whole blood at 250 ×g for 15 min. Serum was 
obtained by further centrifugation of the PRP fraction at 2,000 ×g for 15 min. Serum 
containing <10 kDa proteins was prepared by filtering serum using Amicon® Ultra-4 
centrifugal filter (Millipore; Belerica, MA) at 4,000 ×g for 20 min. All centrifugation was 
conducted under temperature control at 4 oC. Customized needle-type glucose sensors 
(i.e., glucose biosensors without outer-diffusion limiting membrane) were purchased 
from Pinnacle Technologies (Lawrence, KS). Epoxy (5 minute) was purchased from ITW 
Devcon (Danvers, MA) and superflex silicon adhesive sealant was purchased from 
Henkel Loctite Corp. (Rocky Hill, CT). 
5.2.2 Fabrication of NO-releasing needle-type glucose microsensors 
 Nitric oxide-releasing needle-type glucose sensors using S-nitrosothiol-modified 
silica particle (MPTMS/TEOS)-doped polyurethane (PU) membranes were prepared as 
shown in Figure 5.1.   
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Figure 5.1. Schematic diagram of the layered structure of S-nitrosothiol-modified NO-
releasing silica particle (MPTMS/TEOS)-doped polyurethane coated needle-type 
glucose sensors. The resulting electrode is shown to the far right.  
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The fabricated sensors consisted of four distinct layers including an inner-selective layer, 
an enzyme layer, an NO-releasing layer, and an outer-diffusion limiting polyurethane 
membrane. Customized needle-type glucose biosensors purchased from Pinnacle sensors 
were for these studies and came pre-prepared with inner-selective and enzyme layers 
following procedures reported elsewhere.19,23 Exposed electronic parts (e.g., electrical 
wire) were sealed with epoxy and silicon sealants to prevent short circuits prior to 
applying additional layers. Electronic parts were sterilized with CIDEX PLUS® solution 
(3.4% glutaraldehyde) following the manufacturer guidelines. Two exterior membranes 
were coated onto the customized glucose sensors by dip coating. The NO-releasing layer 
required one dip-coat into 72 mg/mL MPTMS/TEOS silica nanoparticle containing 
polymer solution consisting of 80 mg/mL 50% (w/w) TPU/HPU solution dissolved in 50% 
(v/v) THF/EtOH. An additional dip-coat in the same PU solution without particles was 
performed to produce an outermost diffusion-limiting membrane. Each layer was dried at 
ambient conditions for 30 min before coating the subsequent layer. Nitric oxide-releasing 
silica nanoparticles in the NO-releasing layer were synthesized based on a sol-gel process 
via the co-condensation of MPTMS with a backbone silane (75 mol% TEOS), as 
described previously.14 In order to keep topography/roughness constant, control sensors 
were prepared using the same procedure with decomposed MPTMS/TEOS particles. All 
procedures were conducted in a sterilize laminar flow hood. The fabricated sensors were 
placed into individual sterilized centrifuge tubes and kept in a vacuum-sealed sterilized 
bag in the dark at -20 oC until use.  
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5.2.3 Characterization of NO-releasing glucose sensors 
 While the sterilized NO-releasing and control glucose sensors could not be tested 
prior to implantation due to NO donor decomposition, in vitro sensor performance was 
still characterized with one of electrodes from same batch. The analytical performance of 
the glucose sensors was evaluated via amperometry with applied electrode potential +0.6 
V vs. Ag/AgCl using a CH Instruments 1030A potentiostat (Austin, TX), as well as a 
two-channel wireless potentiostat (model 8151 BP; Pinnacle Technology, Inc., Lawrence, 
KS). The electrochemical evaluations were conducted in both 0.01 M PBS (pH 7.4) and 
biological fluids (i.e., PRP and serum) at 37 oC using an integrated Ag/AgCl wire as a 
pseudo counter and reference electrode. Sensor performance criteria (e.g., sensitivity, 
response time, and selectivity) were evaluated as described in Chapter 2 and 4.24 
Morphology of sensor surface was determined via an environmental scanning electron 
microscope (ESEM; FEI company; Hillsboro, OR). Nitric oxide-release properties were 
evaluated using both chemiluminescence and the Griess assay following the methods 
described in previous chapters.24-26 
5.2.4 Implantation and in vivo evaluation of sensor performance 
 The animal protocol used in this study was reviewed and IACUC-approved at 
Duke University. The NO-releasing and control glucose sensors were implanted in mixed 
breed Yorkshire-type piglets weighing approximately 7–12 kg. Pigs were initially 
anesthetized with ketamine:xylazine (20 and 2 mg/kg, respectively) and maintained on 2–
4% isoflurane (v/v in O2) during implantation. After shaving the dorsal fur, the skin was 
prepared by further hair clipping and triplicate scrubbing with chlorhexidine and alcohol. 
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Two incisions (~1 cm) were created 4 cm lateral to the dorsal midline and approximately 
8 cm caudal to the scapulae using a scalpel. One NO-releasing sensors and one control 
sensor were implanted in each subcutaneous incision pocket created by blunt surgical 
scissors (total 4 sensors/pig), and the incisions sutured shut in order to minimize 
micromotion of percutaneously implanted sensors. Implanted sensors were connected 
with a wireless potentiostat (Pinnacle Technologies; Lawrence, KS) having its own 
telemetry channel to allow for real-time measurement in the freely moving pigs. All 
systems were tagged down with a film dressing (i.e., 3M tagaderm) and gauze. 
Additionally, each pig wore a life jacket (O'rageous®; Katy, TX) to further secure the 
electronics. Immediately following sensor insertion, continuous sensor recording (sample 
rate of 1 sample/s) was initiated to determine run-in time. On days 1, 4, and 7, blood 
glucose data was collected from the pigs for a period of 6–8 h while continuously 
monitoring subcutaneous glucose concentration via implanted sensors with +0.6 V vs. 
Ag/AgCl applied potential. After recovering from anesthesia, blood glucose 
measurements were taken from pig ear veins every 10 min using a 30-gauge lancet and 
an One Touch Ultra glucometer (LifeScan Inc.; Milpitas, CA). Typically, the first 3 h 
were used to measure blood glucose fluctuations at steady state. After this time, a glucose 
bolus consisting of a known volume of syrup (100 calories and 18 g sugar per 60 mL) 
was administered orally. Measurements were taken as before for a period of 
approximately 3 h or until blood glucose was stable once more. After a period of 2 weeks 
or after all implanted sensors ceased functioning, the pig was sacrificed and the tissue 
surrounding the implants explanted and flashed frozen with liquid nitrogen, and saved for 
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further analysis. Two swine with three of NO-releasing and control sensors for each were 
used in this study.  
5.2.5 Data analysis for sensor accuracy in vivo 
 To determine the accuracy of the implanted glucose sensors throughout dynamic 
blood glucose fluctuation, the point Clarke Error Grid analysis, mean (or median) 
absolute and relative absolute differences (MAD and MARD), and International Standard 
Organization (ISO) criteria were used.27 Such sensor evaluation methods require 
comparison to true blood glucose concentrations as determined using an external finger-
prick glucose sensor. After the electrochemical sensor responses were smoothed with a 1-
minute moving average, implanted sensors were calibrated via a one-point calibration 
using the first point of blood glucose measurement after full recovery from 
anesthesia.28,29 In a one-point calibration, sensitivity (S) is simply determined as the ratio 
of the current reading (I(t)) and glucose concentration (G(t)) based on the assumption that 
the current response without glucose (background current; I0) is negligible. Thus, the 
glucose concentration is then estimated from the response current according to the 
following equation: 
G t = I(t)S      (1) 
 A physiological lag time exists due to the diffusion of glucose from the capillary 
endothelium to interstitial fluid. This lag time is influenced by the rate of glucose 
diffusion, the rate of glucose uptake by subcutaneous cells, the metabolic rate of the 
adjacent cells, the glucose supply, blood flow, and permeability of the capillary.30 Thus, 
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an average experimentally determined physiological lag time (i.e., 5 min) was taken into 
account during data analysis.30-32 The Clarke Error Grid analysis was constructed using 
MATLAB (Mathworks Inc.; Natick, MA).27,33,34 While MAD indicated the propensity of 
the difference between the continuous glucose measurement and reference readings (i.e., 
external blood glucose monitor), the MARD was calculated as the relative deviation of 
implanted sensor from the reference. The MedAD and MedARD were presented as 
median values rather than mean values. Using MAD and MARD values, run-in time was 
defined where the initial point showing acceptable accuracy. Both MAD and MARD 
were calculated using the following equations, where interstitial fluid (IF) glucose 
concentration determined by current response from continuous glucose monitoring (CGM) 
system and blood glucose concentration (BG) evaluated by finger prick in vitro glucose 
sensors.30 
MAD= Mean CGM-BG                                               (2) 
MARD= Mean 
CGM-BG
BG ×100                (3) 
 The International Standard Organization (ISO) criteria for an accuracy assessment 
was based on (1) the percentage of CGM readings which show less than 15 mg/dL 
difference from the BG when BG ranges ≤75 mg/dL; and, (2) the percentage of CGM 
readings within 20% difference referencing to BG when BG ranges >75 mg/dL.30 
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5.3 Results and discussion 
5.3.1 In vitro electrochemical glucose sensor performance and nitric oxide release 
properties 
 The NO-releasing and control glucose biosensors were fabricated by doping NO-
releasing silica particles and decomposed particles, respectively, into polyurethane 
membranes coated on customized Pinnacle glucose sensors. An additional PU membrane 
served as the diffusion-controlling layer. Without this layer, the linear dynamic range of 
the sensor was limited with sensitivity significantly affected by oxygen concentration due 
to an oxygen deficit.35 Limiting glucose diffusion is especially critical for in vivo glucose 
measurements due to oxygen consumption by inflammatory cells. Thus, a wide dynamic 
range over physiological glucose concentrations (i.e., >12 mM) with sufficient sensor 
sensitivity (i.e. 1.5–3.5 nA/mM) is required for minimizing potential oxygen influence in 
vivo.35 As shown in Figure 5.2, applying the NO-releasing and diffusion-limiting 
polyurethane layers extended the linear dynamic range from 3 to 27 mM, but decreased 
sensor sensitivity from 25.1 to 3.3 ± 2.0 nA/mM. The response time also increase slightly 
from 3.5 to 4.8 s. Despite the sensitivity loss caused by the additional polyurethane 
membranes, the resulting sensitivity was sufficient for in vivo determination.4 As 
fabricated, the glucose sensors were stable for ~21 d with a constant applied potential of 
+0.6 V vs. Ag/AgCl in PBS at room temperature. The selectivity coefficients of the 
resulting sensors—the logarithmic form of the amperometirc sensitivity (∆I/C) for the 
interferent over glucose—were 0.42, 0.62, and -0.03 for ascorbic acid, uric acid, and urea, 
respectively, showing sufficient selectivity of glucose over electroactive molecules at the  
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Figure 5.2. (A) Calibration curves for the needle-type customized Pinnacle sensor (●) 
and fabricated NO-releasing sensor (○) in pH 7.4 PBS at room temperature with 
applied potential +0.6 V vs. Ag/AgCl. (B) Amperometric response of NO-releasing 
sensors upon sequential addition of 1 and 3 mM glucose (Glu) and 100 µM ascorbic 
acid, uric acid, and urea.  
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Table 5.1. Glucose sensitivity changes in various biological fluids.a 
Biological Fluid Sensitivity (nA/mM) 
Normalized 
sensitivity 
Sensitivity decrease 
(%) 
PBS 1.55 1.00 - 
Serum <10 kDa 0.95 0.61 38.7 
Serum 1.06 0.68 31.6 
Platelet Rich Plasma 1.04 0.67 32.9 
Whole Blood 0.81 0.52 48.0 
PBS  
(after washing)b 1.48 0.95 4.8 
a One sensor was used for all experiment to show relative sensitivity change  
b The sensor was washed after operation in all biological fluids. 
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endogenously presented concentration and no synergetic/inhibitory reaction in the 
presence of these compounds.36 Of note, no significant difference in sensor performance 
between control and NO-releasing sensors was observed on the bench top experiments. 
As such, the fabricated NO-releasing glucose sensors met criteria for further in vivo 
testing. 
 Although in vitro sensor characterization does not necessarily predict in vivo 
performance, the variation in sensor sensitivity between various biological fluids was 
determined to simulate more challenging environments. Significantly decreased 
sensitivity was observed in serum containing only <10 kDa proteins, but was restored 
after washing with PBS (Table 5.1). The sensitivity loss in vivo is known to be reversible, 
but occurs immediately following implantation due to protein absorption (<15 kDa) by 
serum albumin and other protein fragments.37 Thus, a ~50% decrease in sensor sensitivity 
was expected upon contact with subcutaneous tissue in vivo. Nevertheless, the 
sensitivities of the fabricated NO-releasing sensors proved adequate in the biological 
fluids investigated, again setting the stage for the in vivo. 
 The S-nitrosothiol (RSNO)-modified silica nanoparticles were synthesized as an 
NO donor and characterized with respect to NO-release. As expected, these particles 
exhibited greater NO storage (2.95 ± 0.25 µmol/mg) with prolonged NO release 
durations (half-life 213 ± 20 min and duration >48 h in PBS at 37 oC).14 Particle leaching 
from the polyurethane membranes was not observed, likely due to the large particle size 
of MPTMS/TEOS (~700 nm), eliminating toxicity concerns.15  
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Figure 5.3. Nitric oxide-release profile from 72 mg/mL MPTMS/TEOS 
particle-doped 50% (w/w) TPU/HPU polyurethane membrane coated 
needle-type glucose biosensors. Inset represents integrated total NO 
release.  
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 The NO release from MPTMS/TEOS particle-doped polyurethane membranes 
was evaluated in PBS (pH 7.4) at 37 oC to mimic physiological conditions. The 
membranes exhibited a maximum NO flux of 196.7 ± 2.9 pmol cm-2 s-1 and total NO 
release of 1.3 ± 0.8 µmol cm-2 (Figure 5.3). The NO-release properties of the particles 
agreed with that of previously reported NO-releasing xerogels that displayed ~50% less 
collagen capsule formation and chronic inflammation versus in rodent model.11 
Additionally, the MPTMS/TEOS particle-doped PU membranes showed significantly 
reduced collagen encapsulation in the porcine subcutaneous tissue due to longer NO-
release duration (i.e., 14 d) since the RSNO-modified silica particles allowed the release 
of NO at low fluxes over extended periods through a thermal release mechanism.15 
Although the fabricated glucose sensor membrane exhibited >24 h NO-release duration 
due to the limited thickness of the coating employed for the functional glucose sensors, 
the low levels of NO still being released but analytically undetectable (by NOA) may still 
mitigate the FBR.  
5.3.2 In vivo glucose sensor performance  
 In vivo sensor performance was evaluated in a freely moving porcine model. Both 
NO-releasing and control sensors were implanted percutaneously and amperometric 
current response was immediately monitored under an applied electrode potential of +0.6 
V vs. Ag/AgCl. Standard polarization curves from both NO-releasing and control glucose 
sensors were observed and stabilized ~30 min after implantation. After the pig recovered 
from anesthesia (i.e., approximately 1.5 h after implantation), the first blood glucose 
measurement was carried out using a conventional glucometer via ear pricking. The 
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experimentally determined run-in time was 3.4 h with MAD (MARD) of 14.6 (13.5) and 
7.5 (6.9) for control and NO-releasing glucose sensors, respectively. The NO-releasing 
sensors demonstrated ~50% greater accuracy at the initial time point compared to control 
sensors. Gifford et al. showed practically same results that the NO-releasing sensors 
exhibited a short time (~30 min) for reaching to stable basal response versus control 
sensors (4–10 h) in a rodent model.19 In other words, the NO-releasing sensor showed 
greater accuracy at a certain initial time point compared to controls due to fast 
stabilization after implantation. 
 The numerical accuracies of both control and NO-releasing glucose sensors were 
further evaluated as a function of implantation period. In terms of analytical accuracy, a 
greater percentage of points in zones A and B of the Clarke Error Grid and International 
Standard Organization (ISO) criteria represent superior performance in vivo. Lower 
values of MAD (MARD) and MedAD (MedARD) represent better accuracy.  
 As shown in Table 5.2, the NO-releasing sensors achieved ~6.5% greater 
accuracy on the Clarke Error Grid analysis on day 4 and 7 compared to controls, while 
~2.7% less accurate on the day after implantation. In contrast, the overall value of MAD 
(MARD) and MedAD (MedARD) values suggested the control sensors were slightly 
more accurate than the NO-releasing glucose sensors on day 1 and 4. However, the NO-
releasing sensors exhibited slightly better accuracy on day 7 compare to the controls 
based on MedAD and MedARD analysis. 
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Table 5.2. In vivo numerical and clinical accuracy of control and NO-releasing sensors 
as a function of implantation period.a 
Implant period (d) 1 4 7 
Glucose sensor Control NO Control NO Control NO 
Percent of points in 
Zone A and B  
of Clarke Error Grid 
94.6 91.9 82.5 88.5 93.3 100 
Number of data points 140 136 47 85 70 37 
MedADb 17.1 20.1 15.9 17.6 22.9 11.0 
MedARDc 13.9 17.0 17.4 18.6 48.0 35.5 
MADd 27.4 36.6 60.5 61.2 30.1 30.9 
MARDe 22.2 34.7 28.7 29.5 49.1 38.9 
ISO (≤75 mg/dL; %)f 43.5 34.8 82.4 84.6 47.9 91.7 
ISO (>75 mg/dL; %)f 61.6 59.2 47.5 41.4 3.7 0.0 
a Two swine with three of NO-releasing and control sensors for each were used. 
b Median absolute differences (MedAD) 
c Median relative absolute differences (MedARD) 
d Mean absolute differences (MAD) 
e Mean relative absolute differences (MARD) 
f  International standard organization (ISO) criteria: (1) percent reading less that 15 mg/mL difference from 
in vitro blood glucose (BG) measurement when BG ranges ≤75 mg/dL), and (2) percent reading of 
implanted glucose sensors within 20% difference referencing to BG when BG ranges >75 mg/dL. 
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 Although the longest sensor lifetime in vivo was 2 weeks, ~50% of both control 
and NO-releasing sensors were failed before a week time point. Interestingly, 75% of 
sensors with a first trial pig (7 kg) were worked for 2 weeks, while all sensors with a 
second trial pig (12 kg) failed after 4 d. These results suggested that greater mechanical 
stress due to the animal size may critically affect on the sensor lifetime in vivo. 
 According the ISO criteria evaluation, the NO-releasing sensors were more 
accurate than controls in hypoglycemia region after one-week of implantation. However, 
the total number of data points for NO-releasing sensors was less than for controls due to 
sensor failure. For example, only 37 data points were analyzed on day 7, half of that 
collected from the controls. The sensor failure was attributed to electrical connection 
problems mainly due to mechanical stress on the sensor components.  
 A comparison of the in vivo sensor performance of NO-releasing sensors relative 
to control sensors was also carried out using accumulated data points. As shown in Figure 
5.4 and Table 5.3, both the NO-releasing and control sensors had 91.8% of points in 
Zones A and B of the Clarke Error Grid, indicating clinically accurate and acceptable 
determinations, respectively. While NO-releasing sensors yielded more points in the 
clinically acceptable zone compared to controls (~8%), the control sensors exhibited 
more data within the clinically accurate zone (166 vs. 159 for controls and NO-releasing 
sensors, respectively). The percentage of points for NO-releasing and control sensors in 
Zone E, leading to hyperglycemia treatment for hypoglycemia or vice versa, were similar 
(3.9 and 3.6%, respectively).  
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Figure 5.4. Clarke Error Grid analysis for (A) controls and (B) NO-releasing sensors 
(n=2 pigs and n=3 sensors). Presented data were cumulative results for one-week 
implantation.  
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Table 5.3. Total number of data points and percent points in the zone of the Clarke Error 
Grid analysis.a 
Clarke Error Grid Zone 
Control NO-releasing 
Total Percentage (%) Total Percentage (%) 
A 166 59.3 159 56.6 
B 91 32.5 99 35.2 
C 0 0.0 6 2.1 
D 13 4.6 6 2.1 
E 10 3.6 11 3.9 
a Data was collected for one week from two swine with three sensors for each type. 
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Of note, the NO-releasing sensor exhibited a lower percentage of measurements in Zone 
D indicating a potentially dangerous failure to detect hypoglycemic or hyperglycemic 
events. Overall, results using the NO-releasing and the control sensors were not 
significantly different based on Clarke Error Grid analysis regarding to the clinical use.  
 According to a power analysis which is statistical determination of sample size 
required to discover a significant effect,38 twenty animals are required to detect small 
differences (i.e., ~2%) at a confidence interval (α) of 0.05 using a two-tailed t-test with a 
power of 0.8. Thus, inconclusive result presented herein is clearly due to the limited 
sample size. Additionally, the subject’s disease state (healthy vs. diabetes) may contribute 
to weak correlations. Since pigs with diabetic mellitus are known to have an NO 
deficiency, compromised immune system, and less wound healing,39 diabetic pigs may be 
more suitable for future studies. 
 Aside from the Clarke Error Grid analysis, other numerical accuracy tests were 
also conducted and presented in Table 5.4. While MedAD (MedARD) values suggested 
the NO-releasing sensor exhibited slightly improved accuracy compared to controls, 
comparisons of the MAD (MARD) values showed opposite results. However, the ISO 
criteria analysis revealed that the NO-releasing sensors were more accurate in 
hypoglycemic events compare to the controls. Of note, hypoglycemic events often result 
in more serious side effects including unconsciousness, brain damage and even death. 
Thus, the evaluation of the NO-releasing sensors with insulin administration for inducing 
hypoglycemia may greatly enhance the impact of the study.   
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Table 5.3. The numerical accuracy test of implanted glucose sensors.a  
In vivo sensor point accuracy Control NO-releasing 
Percent point at Zone A and B of Clarke 
Error Grid analysis 
91.79 91.81 
MedADb 18.6 17.6 
MedARDc 23.2 20.7 
MADd 34.8 38.9 
MARDe 30.7 32.4 
ISO (≤75 mg/dL)f 54.5 72.6 
ISO (>75 mg/dL)f 50.5 49.5 
a Two swine with three of NO-releasing and control sensors for each were used. 
b Median absolute differences (MedAD) 
c Median relative absolute differences (MedARD) 
d Mean absolute differences (MAD) 
e Mean relative absolute differences (MARD) 
f  International standard organization (ISO) criteria: (1) percent reading less that 15 mg/mL 
difference from in vitro blood glucose (BG) measurement when BG ranges ≤75 mg/dL), and (2) 
percent reading of implanted glucose sensors within 20% difference referencing to BG when BG 
ranges >75 mg/dL. 
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5.4 Conclusions 
 Percutaneously implanted both control and NO-releasing sensors in a freely 
moving porcine model exhibited 91.8% points in clinically accurate and acceptable 
ranges on the Clarke Error Grid analysis. While subcutaneously implanted polyurethane 
films doped with S-nitrosothiol-modified silica particles showed less collagen 
encapsulation and reduced inflammatory response,15 glucose sensors coated with these 
membranes did not result in significant improvements in sensor accuracy or sensor 
lifetimes. Limited animal sample size and the disease state, as well as undesirable 
mechanical stress that may have induced a more pronounced FBR may have caused 
insignificancy. Specifically, mechanical stress provoking sheer force and thus reducing 
tissue integration may conceal the effect of NO on the FBR. Therefore, a more 
biocompatible NO-releasing sensor membrane designed to further enhance tissue 
integration and thus minimize mechanical stress is required along with NO-release. In 
turn, the NO-releasing porous electrospun fiber membrane-modified needle-type glucose 
sensor may enhance in vivo sensor performance especially implanting in a diabetic 
porcine model.  
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CHAPTER 6: SUMMARY AND FUTURE DIRECTIONS !
6.1 Summary 
 The dissertation research presented herein focused on nitric oxide (NO)-releasing 
biocompatible sensor membranes for developing implantable glucose biosensors that 
function more reliably in vivo. Due to numerous complications (e.g., heart disease, 
kidney failure, blindness, or even death) caused by diabetes, implantable glucose 
biosensors capable of monitoring and strict control of blood glucose levels are essential 
for effective treatment. The utility of implantable glucose sensors is limited due to poor 
tissue biocompatibility and sensor biofouling associated with the foreign body response 
(FBR). My research has focused on the development of NO-releasing sensor membranes 
that may mitigate the FBR, reduce bacterial adhesion, enhance wound healing, and thus 
improve analytical performance in vivo. Both film and porous NO-releasing polyurethane 
membranes were developed with controlled release capabilities and coated on needle-
type implantable electrochemical sensors for continuous glucose monitoring. 
 In Chapter 2, the fabrication of NO-releasing silica particle-doped polyurethane 
glucose sensor membranes was described to control NO-release kinetics and sensor 
performance. Nitric oxide-releasing silica particles were embedded in polyurethane films 
and utilized as sensor membranes. The NO-release properties and performance of sensors 
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modified with such coatings were characterized. Tunable NO release was achieved by 
altering the type of NO donor (i.e., N-diazeniumdiolate and S-nitrosothiol), amount of 
dopant, as well as the water uptake (i.e., hydrophobicity) and concentration of 
polyurethane. For example, the NO-release duration was extended from 25 h to 4 d by 
adding a hydrophobic water barrier polyurethane layer (i.e., Tecoplast) and tuning the 
concentration of polyurethane. Of note, the NO-release vehicle and the NO-release 
kinetics did not affect glucose sensor performance (e.g., sensitivity). Selectivity for 
sensing glucose over NO was achieved by using an electrode potential of +0.6 V vs. 
Ag/AgCl to avoid NO oxidation. Along with the controlled NO release, increased the 
sensor membrane thickness and hydrophobicity of the polyurethane film decreased 
glucose sensor sensitivity and increased response time and the dynamic range. These 
results illustrate the capability of controlled nitric oxide release with enzymatic 
biosensors regarding to sensor performance.  
In Chapter 3, electrospun polyurethane fibers doped with NO-releasing silica 
particles were studied to take advantages of both active and passive strategies that may 
mitigate the FBR. The fiber diameter and mechanical strength of the electrospun fibrous 
mats were varied by altering the concentration and type of the polyurethane solution, as 
well as the concentration of NO-releasing silica particles. The fabricated NO donor-
doped electrospun nanofibers (150‒630 nm) exhibited ~83% relative porosity, with 
flexible plastic or elastomeric behavior depending on polyurethane composition. A wide 
range of NO-release kinetics and totals (i.e., total NO release of 7.5‒120 nmol mg-1 with 
release durations from 4 h to 2 weeks) were achieved by selection of appropriate NO 
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donor-modified silica particles, varying the NO donor concentration, and/or altering 
polyurethane composition. While silica particles are generally believed not to be 
cytotoxic to subcutaneous tissue,1 the NO-releasing silica particles leached from the 
electrospun polyurethane fibers causing concern. Leaching from these fibers was 
minimized by increasing particle size and/or the hydrophobicity of the polyurethane.  
 In Chapter 4, needle-type implantable glucose sensors were fabricated with NO-
releasing polyurethane electrospun fibers as a possible method to improve the 
biocompatibility of continuous glucose monitoring systems. Although the level of silica 
particle leaching from the studied membranes in Chapter 3 was lower than the reported 
cytotoxic level, NO-releasing dendrimers were chosen as dopants for the electrospun 
fibers. N-diazeniumdiolated 1,2-epoxy-9-decene (ED) functionalized fourth-generation 
poly(amidoamine) (PAMAM) dendrimers are characterized by diverse NO-release 
kinetics.  They also possess exterior chemical moieties that undergo facile modifications. 
After confirming minimal leaching with this NO donor, NO-releasing porous membranes 
were applied to needle-type glucose sensors as an outermost membrane via 
electrospinning. The fabricated electrospun fiber membrane maintained its porous 
structure in serum. Electrospinning allowed direct coating of the needle-type glucose 
sensors with variable chemical and physical properties without compromising sensor 
function.  
In Chapter 5, NO-releasing needle-type glucose sensors were percutaneously 
implanted in a freely moving healthy porcine model to assess in vivo sensor accuracy. 
Numerical accuracy criteria were used to compare the analytical performance of NO-
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releasing vs. control biosensors. Both the NO-releasing and control glucose sensors 
showed 91.8% points in the clinically accurate and acceptable ranges of the Clarke Error 
Grid analysis. However, the small sample size precluded any conclusion regarding the 
benefits of NO release on sensor performance. Furthermore, many of the sensors suffered 
from undesirable mechanical stress caused by the orientation of percutaneous implants. 
This in turn may have obscured the effect of NO release on the FBR.  
6.2  Future Directions 
6.2.1  Topography controlled co-axial electrospun fibers 
 The high degree of controllable NO release from N-diazeniumdiolate- and S-
nitrosothiol-modified NO donor-doped polyurethane films and fibers were described for 
use as implantable glucose sensor membranes. Since extended NO release from 
membranes has been shown to be important for mitigating the FBR,2 longer NO-release 
durations were achieved by increasing the hydrophobicity and/or thickness of the water 
barrier layers described in Chapter 2. As presented in Chapter 3 and 4, the controllability 
of NO-release kinetics from electrospun fibers using N-diazeniumdiolate-modified NO 
donor was however limited to the high porosity of the fiber mats and the lack of a barrier 
layer around the NO donors. Additionally, the electrospun fibers were oriented randomly 
while aligned fibers have been shown to foster greater cell proliferation and indistinctive 
fibrous capsulation boundary in vivo.3 
 Extending this research, co-axial electrospun fibers—possessing a core-sheath 
biocomponent nanofiber structure—may enhance the ability to control and tune the NO 
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release from polyurethane fibers.4 To fabricate co-axial electrospun fibers, two dissimilar 
or antithetical materials are independently fed into a co-axial spinneret (e.g., concentric 
needles of different sizes) generating a core-sheath configuration.4 Especially for 
biomedical applications, these types of fibers hold advantages including: (1) isolation of 
an unstable component to prevent undesired decomposition under a reactive environment; 
(2) controlled release of therapeutic agents from the core by modifying sheath 
composition; and, (3) reinforcement of chemical and physical properties by surrounding 
core with biocompatible sheath materials.4 The use of various polymeric NO-release 
scaffolds in the core and hydrophobic polymers as a sheath may enable to control over 
NO release. For example, the NO-releasing core could consist of N-diazeniumdiolated 
xerogels and chitosan or any other NO donor-doped polymer (e.g., dendrimer-doped 
hydrogel or hydrophilic polyurethane). The sheath layer could consist of hydrophobic 
polyurethane, polyvinyl chloride, or silicon rubber to reduce water diffusion and thus 
further extend NO release duration. The sheath may also prove useful in reducing the 
cytotoxicity of certain scaffolds (e.g., dendrimer) to surrounding tissue. To fabricate NO-
releasing co-axial electrospun fibers, the following parameters should be evaluated 
during electrospinning process: electrospinnable solution viscosity and conductivity of 
the sheath polymer; interfacial tension between the sheath and the core solution to allow 
stable Taylor cone formation; and, solvent vapor pressure.4 In addition to these 
parameters, the applied voltage and feed rates should also be considered.4  
 In addition to fabricating NO-releasing co-axial electrospun fibers, the 
morphology of fiber mats should be studied. Since the FBR is affected by both the NO 
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release2 and implant topography,3 varying the orientation of the NO-releasing fibers may 
also prove useful. Aligned electrospun fibers can be fabricated by changing the collector 
geometry to manipulate the electric field (e.g., parallel electrodes) and/or using a 
dynamic collector (e.g., rotating drum collector).5 As shown in Figure 6.1, aligned fibers 
can be achieved by modifying the electric field using a window-type metal collector. In 
this regard, a rectangular gap (i.e., window) on the disk type collector can be used to 
collect aligned fibers.6 Random fibers are also observed on the solid part of the disk 
collector, highlighting the ability to simultaneously collect both aligned and random 
fibers. Three-dimensional substrates (e.g., implants or sensors) can be coated with 
aligned fibers by rotating the substrate in the void of this collector type. These 
preliminary results indicate the potential for controlling the morphology of fibrous 
membranes on needle-type glucose sensors.  
 The porosity of the fibers can also be tuned by changing the polymer solution 
flow rate, the rotation speed of the drum collector and the collector type (e.g., spherical 
dish and frame cylinder).7,8 Although the porosity control of electrospun fibers is 
challenging, lower feed rate or rotating speed generally results in greater porosity.8 
Alternatively, co-electrospinning with a sacrificial polymer can be utilized to increase the 
pore size of fiber mat creating pores by dissolving away sacrificial polymer in a solvent 
that has no effect on the structure of the polymer of interest.7 
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Figure 6.1. Environmental scanning electron microscopy (ESEM) images of (A–C) 
aligned and (D–E) random fibers collected on the window type of metal collector. 
Tecophilic (A and D), Tecoflex (B and E), and Tecoplast (C and F) polyurethane were 
electrospun on this collector. Insert of each ESEM image is the fast Fourier transform 
images of spatial frequency of fibers.  
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Fibers having significantly extended NO release duration with various morphologies via 
co-axial electrospinning may open up the potential for other biomedical applications, 
advancing these materials not only as implantable sensor membranes but also wound 
dressings and tissue engineering scaffolds.  
6.2.2  The topographical effect of localized NO delivery on the foreign body response  
 Although advantages of NO-release materials and electrospun fibers mitigating 
the FBR have been reported independently, the effect on the FBR using combined NO 
release and porous structure scaffolds has not yet been studied. As an extension of the 
results described in Chapter 2, Nichols et al. reported the effects of NO-release kinetics 
on the FBR by varying the NO-release duration from hours to weeks.2 S-nitrosothiol-
modified silica particle-doped polyurethane films (NO-release duration of ~2 weeks) 
most significantly reduced capsule thickness after 3 weeks of implantation. Likewise, 
Cao et al. published on the topographical effect of both random and aligned electrospun 
poly(ε-carprolactone) nanofibers on the FBR in a rodent model, showing less collagen 
capsule formation compared to film implants. Based on the promising results from both 
studies, the topographical effects (e.g., non-porous vs. porous and/or random vs. aligned) 
of implants with and without NO-release ability should also be studied as a function of 
NO-release kinetics, and electrospun fiber mat properties (e.g., porosity and alignment).  
 Researchers often use rodent (e.g., mouse and rat) and porcine models to assess in 
vivo biocompatibility, though others (e.g., dog, rabbit, and chimpanzees) have been used 
as well.9 While the rodent models is often selected due to cost, the porcine model is more 
ideal for tissue implant studies as pig skin closely resembles that of humans.10 
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Additionally, the vascular and immune system of the pig and human have a high degree 
of similarity.10 It has been reported that diabetic subjects exhibit an NO deficiency 
associated with the breakdown of NO, causing impaired insulin-mediated vasodilation 
and glucose metabolism.11 Thus, a diabetic porcine model should be considered for future 
work since diabetic patients may have delayed and diminished wound healing, 
physiological responses affecting sensor performance.12,13 
 Since the FBR is a sequential event, NO release and porous features may 
distinctly affect the inflammatory response depending on the FBR phases. A time-
dependent investigation (e.g., 1 and 3 d; and 1 and 4 week for acute and chronic 
inflammatory stages, respectively) is thus needed to determine the effects of NO release 
and porosity on each stage of the FBR, with histological analysis.  
6.2.3  Percutaneous implantation of nitric oxide-releasing porous membrane coated 
sensors for real-time glucose monitoring in healthy and diabetic porcine model. 
 Optimized NO-releasing electrospun fibers could be applied to functional needle-
type glucose sensors as described in Chapter 4. In vivo sensor performance could be 
evaluated in diabetic and healthy pigs as described in Chapter 5. Optimal NO-releasing 
porous membranes may concomitantly allow for improvement of in vivo sensor 
performance and increased sensor lifetime. Implanting these glucose sensors in diabetic 
pigs may further highlight the prominent effects of NO-releasing porous membranes. 
Along with histological evaluation, demonstration of quantitative electrochemical 
analysis based on clinical utility may greatly advance the development of continuous 
glucose monitoring systems. 
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 Although numerical accuracy analysis compared to blood glucose concentration 
using a conventional glucose sensor is usually conducted at certain time points, a 
quantitative analysis of the rate and direction change is often ignored. Such trends via an 
implantable glucose sensor are important, and have been proposed (with appropriate 
algorithms) as necessary for developing the artificial pancreas. Both the point- and rate-
Clarke Error Grid analysis should be demonstrated using glucose challenges.14 
Administrating glucose through a catheter (i.e., intravenous glucose tolerance test 
(IVGTT) should enable a significant change in glucose concentration, especially in 
diabetic pigs. Additionally, insulin injections using commercially available insulin pens 
can be used to create a hypoglycemic event. Alternatively, a triphasic glycemic pattern 
following sterptozotocin injection (initial hyperglycemia peak ~60 min duration and 
secondary hypoglycemia ~4 h duration preceding the establishment of permanent 
hyperglycemia) could be used as a way to realize more spontaneous changes in blood 
glucose level over a larger concentration ranges.15 Such studies may provide reliable 
quantification of sensor accuracy and enable determination of anticipated dual benefits of 
NO release and porosity.  
 Ultimately, more biocompatible and accurate implantable sensors should be 
integrated with an insulin pump to allow the automatic administration of insulin and thus 
improved regulation of blood glucose concentrations. Such an artificial pancreas would 
greatly improve the lives of diabetes patients and decrease the morbidity and mortality 
associated with diabetes mellitus.  
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